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Abstract 
Background: In addition to lowering low density lipoprotein-cholesterol (LDL-C), statin therapy also 
raises high density lipoprotein-cholesterol (HDL-C) levels. Inter-individual variation in HDL-C 
response to statins may be partially explained by genetic variation.  
Methods and Results: We performed a meta-analysis of genome-wide association studies (GWAS) to 
identify variants with an effect on statin-induced HDL-C changes. The 123 most promising signals 
with P<1x10
-4
 from the 16,769 statin-treated participants in the first analysis stage were followed up 
in an independent group of 10,951 statin-treated individuals, providing a total sample size of 27,720 
individuals. The only associations of genome-wide significance (P<5x10
-8
) were between minor 
alleles at the CETP locus and greater HDL-C response to statin treatment.  
Conclusion: Based on results from this study that included a relatively large sample size, we suggest 
that CETP may be the only detectable locus with common genetic variants that influence HDL-C 
response to statins substantially in individuals of European descent. Although CETP is known to be 
associated with HDL-C, we provide evidence that this pharmacogenetic effect is independent of its 
association with baseline HDL-C levels.  
Keywords: Pharmacogenetics, HDL-Cholesterol, Statins, Genome-wide association study 
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Introduction 
The drug class of 3-hydroxymethyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, 
better known as “statins”, are widely prescribed and effective for the prevention and management 
of cardiovascular disease (CVD).[1] While the major CVD benefit of statins is due to reduction in 
plasma low density lipoprotein cholesterol (LDL-C)[2], statins also produce moderate increases, 
ranging from 4 to 10%, in levels of high density lipoprotein cholesterol (HDL-C).[3 ,4] This is of 
particular interest since HDL-C levels are inversely related to CVD risk in the general population and 
in patients treated with statins.[5 ,6] However,  a causal role of low HDL-C as a determinant of 
increased CVD risk is controversial.[7]  
The increase in HDL-C after statin therapy varies among individuals.[3] This might be partly due to 
genetic variation. Previous studies that have investigated associations between genotype and statin-
induced changes in HDL-C[8-10] have focused primarily on variants within the CETP gene that are 
known to affect circulating HDL-C levels[11] and risk of coronary artery disease.[12] To address 
whether additional loci have an effect on statin-induced changes in HDL-C levels, we conducted a 
large-scale meta-analysis of genome-wide association studies (GWAS) using datasets from both 
randomized controlled trials (RCTs) and cohort studies in the large Genomic Investigation of Statin 
Therapy (GIST) consortium that previously identified four loci associated with LDL-C response to 
statins.[13]  
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Methods 
Study populations 
The GIST consortium assembled data from seven RCTs and eleven prospective population-based 
studies. The initial analysis (first stage) was performed in 16,769 statin-treated individuals; 8,506 
individuals from six RCTs (ASCOT UK, CARDS, CAP, PRINCE, PROSPER, and TNT) and 8,263 statin-
treated individuals from ten observational studies (AGES, ARIC, ASCOT UK-observational, BioVU, 
CHS, FHS, Health ABC, HVH, MESA, and the Rotterdam Study). Further investigation (second stage) 
was performed in 10,951 statin-treated individuals from two RCTs (ASCOT Scandinavia and JUPITER) 
and two observational studies (ASCOT Scandinavia – observational and GoDARTS), which were used 
to test for replication of findings from the first stage. Details of the first and second stage studies, 
including their genotyping and quality control (QC) information, can be found in the Supplementary 
Notes 1, 2 and 3 and Supplementary tables 1 and 2. 
Subjects 
Response to statin treatment was principally studied in statin-treated individuals only. Those treated 
with placebo were excluded from the analyses of RCTs and those not treated with statins were 
excluded from observational studies. HDL-C measurements were obtained before and after start of 
statin treatment. Only subjects with non-missing phenotypes and covariates were included. Those of 
reported or suspected non-European ancestry were excluded.  
Outcome measurements 
The response to statin treatment was defined as the difference between the natural log-transformed 
on- and off-treatment HDL-C levels (ln (on-treatment HDL-C) – ln (off-treatment HDL-C)). The 
corresponding linear regression coefficients thus reflect the fraction of differential HDL-C increase 
(relative increase) per copy of the coded allele in the additive genetic model. For observational 
studies, on-treatment HDL-C levels were calculated for all different prescribed statins, at any dosage, 
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for any indication, and for any treatment episode extending at least four weeks prior to on-
treatment HDL-C measurement. Characteristics of on- and off-treatment HDL-C levels and statins 
used in each study are shown in Supplementary Table 2. For each individual, at least one off-
treatment HDL-C measurement and at least one on-treatment measurement were required. 
Subjects with missing on- or off-treatment measurements were excluded, with the exception of the 
GoDARTS study for which missing off-treatment HDL-C levels were estimated using imputation 
methods, as described previously.[14] In RCTs, when multiple on- or off-treatment measurements 
were available, the mean of the measurements was used. 
Genotyping and imputation 
Genotyping, quality control, data cleaning and imputation were performed independently in each 
study using different genetic platforms and software as outlined in Supplementary Table 3. In all 
studies, genotyping was performed using either Illumina, Affymetrix, or Perlegen genotyping arrays. 
Genotype data from each study had been imputed to the HapMap phase 2 reference panel [15] , 
except for JUPITER which was imputed to the 1000genomes pilot data, using either MACH, Impute, 
or BIMBAM software [16-18], resulting in a total of approximately 2.5 million SNPs for analysis. 
GWAS analysis 
Each study independently performed the GWAS on the difference between natural log-transformed 
on- and off-treatment HDL-C levels, according to a common, central analysis protocol. To reduce 
confounding by possible association with off-treatment HDL-C levels, analyses were adjusted for the 
natural log-transformed off-treatment HDL-C levels. Linear regression was used, with SNPs 
represented by an additive genetic model and with imputed SNPs represented by expected allele 
dosage. Analyses were additionally adjusted for age, sex, and study specific covariates (e.g ancestry 
principal components (PCs), site, or country). FHS made use of a linear mixed effects model 
considering the kinship matrix in the analysis, hereby accounting for familial correlations within FHS. 
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Analyses in the observational studies were, if the information was available, additionally adjusted for 
the time interval between on- and off-treatment HDL-C measures (mean follow-up times per study 
are provided in Supplementary Table 2) and for the natural logarithm of the statin dose equivalent, 
as defined in Supplementary Table 4. This table shows the dose for different statins for the LDL-C 
response; dividing the statin dosage for an individual drug by its dose equivalent shown in 
Supplementary Table 4 gives the standardized statin dosage.  
Quality control and Meta-analysis 
Within each study, SNPs with minor allele frequency <1% or imputation quality <0.3 were excluded 
from the analysis. QQ-plots were assessed for each study to check that there were no between study 
differences nor evidence for systematic bias within studies (Supplementary Figure 1). The software 
package METAL was used to perform the meta-analysis.[19] A fixed effects, inverse variance 
weighted approach was used. To correct for possible inflation of the test statistic, e.g. due to small 
amounts of potential population sub-structure, genomic control was performed by adjusting the 
within-study findings and the meta-analysis results for the genomic inflation factor. 
Second stage 
SNPs with p-values <1x10
-4
 in the first stage meta-analyses were selected for further investigation in 
the second stage. A maximum of two SNPs per locus (with a maximum 100 kB distance between 
SNPs) were selected, with the choice based on statistical significance. A total of 123 SNPs in 83 loci 
were selected for the second stage, which was performed in the GoDARTS study, the JUPITER trial, 
and the RCT and observational arm of the ASCOT Scandinavia study. GWAS data and response to 
statin treatment were available for these studies. Analysis was performed as for the first stage. 
Results of the first and second stage were combined using a fixed effects, inverse variance weighted 
meta-analysis using METAL.  
Interaction analysis 
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The interaction effect of the lead CETP SNP rs247616 with the binary treatment indicator for statin 
versus placebo allocation was assessed in five of the participating RCTs (ASCOT Scandinavia, ASCOT 
UK, CARDS, JUPITER, and PROSPER). For these analyses, placebo treated individuals in the RCTs were 
included. The total sample size was 17,857, with 8,978 statin treated individuals and 8,879 placebo 
treated individuals. Regression models were applied to the combined population of statin and 
placebo treated subjects by adding to the model extra terms including treatment (statin (=1) or 
placebo (=0)) allocation and the product of treatment allocation with SNP minor allele dose.[20] 
Interaction coefficients of the five studies were combined in a fixed effects, inverse variance 
weighted meta-analysis using METAL. In addition, we also performed our main analysis for the CETP 
SNP rs247616 in only the placebo users of the five RCTs included in the interaction analysis.  
Effect of genetic determinants of HDL-C levels on statin-induced HDL-C response 
We performed a look-up in our GWAS results for all known genome-wide significant genetic variants 
associated with HDL-C levels, obtained from the most recent Global Lipids Genetics Consortium 
(GLGC) paper.[11] Of the 80 variants, 78 were available in our GWAS on statin induced HDL-C 
response. Subsequently, we examined whether a multi-SNP genotypic risk score constructed from 
these GLGC variants was associated with the level of statin induced HDL-C response, using publicly 
available summary level data from the GLGC 
(http://csg.sph.umich.edu//abecasis/public/lipids2013/). The joint effect of the 78 genetic variants 
on statin-induced HDL-C response was examined by means of a data-driven inverse-variance 
weighted approach, described previously by Dastani et al,[21] and accomplished through the gtx-
package[22]
 
(Genetics ToolboX, http://cran.r-project.org/web/packages/gtx) in the R statistical 
software environment.[23] Analogous to deriving a pooled estimate from the results of individual 
studies in conventional meta-analysis, this approach combines the causal estimates of multiple 
genetic variants, defined as the ratio of their association with statin response to their association 
with HDL-C levels. 
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Conditional analysis 
Conditional analysis were performed in two of the participating studies, ASCOT UK (both RCT and 
observational – genotype data available for n=3,804) and CARDS (genotype data available for 
n=1194). Conditional analysis was conducted within GCTA software[24], using the –cojo method, 
which performs conditional and joint analysis with model selection. The genome-wide meta-analysis 
summary statistics from the combined analysis of both first-stage and second-stage data were used 
as the input data. Analysis was restricted to chromosome 16, containing the only genome-wide 
significant result from the meta-analysis, in order to determine whether the CETP region contains 
more than one independent signal of association. Within the GCTA analysis, MAF was restricted to 
≥1% and a p-value cut-off of 5x10
-7
 was used as the selection threshold. LD was calculated between 
pairwise SNPs, but any SNPs further than 10 Mb apart were assumed to be in linkage equilibrium.  
Variance explained 
Two secondary analyses were performed to investigate the heritability of this pharmacogenetic trait. 
Firstly, the genome-wide heritability was calculated in GCTA[24] by estimating h
2
 using GREML 
analysis, according to all HapMap SNPs with MAF ≥ 1%, with reference to the genomic relatedness 
matrix generated within GCTA. Secondly, the percentage variance explained for the HDL-C response 
to statins adjusted for baseline HDL-C was calculated specifically for the lead CETP SNP rs247616 
using R software[23] by including the dosage data for this SNP as a continuous predictor variable 
within the model. Firstly, the HDL-C response trait was regressed against all non-genetic covariates. 
The residuals from this model were used as the residual trait. In a second stage linear regression 
analysis the residual trait was regressed against the lead SNP and PCs. The R
2
 calculated from this 
second fitted linear regression model was used to estimate the percentage of the trait variance 
explained. Both analyses were performed using the ASCOT-UK dataset, as individual level raw 
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genotype data are required. The combination of both the RCT and observational sub-cohorts of 
ASCOT-UK gave a total sample size of N = 2,055 statin-treated participants. The explained variance 
analysis in R was additionally performed in the CARDS study, including 1,194 statin-treated 
participants. The linear regression models used exactly the same data and covariates as from the 
primary GWAS analysis.   
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Results 
First-stage meta-analysis 
In the first stage of this analysis, six randomized controlled trials (n=8,506 statin recipients) and ten 
observational studies (n=8,263 statin recipients) were included (Supplementary Notes 1 and 2 and 
Supplementary Tables 1 and 2). Three SNPs at the CETP locus (chromosome 16) were identified as 
genome-wide significant (P<5x10
-8
) for their association with HDL-C response to statin treatment 
(Figures 1 and 2 and Table 1). The most significant association was for SNP rs247616 (MAF=0.324, 
β=0.011, SE=0.002, P=5.95x10
-10
) (Figure 3), indicating that carriers of the minor allele of this SNP 
respond to statins with a 1.1% greater per-allele increase in HDL-C compared with non-carriers. The 
average increase in HDL-C during statin treatment across all studies was 0.045 mmol/L. This 
additional 1.1% per-allele increase in HDL-C is equivalent to a 0.046 mmol/L increase for carriers of 
one copy of the CETP SNP. We found no other loci associated with HDL-C response to statin 
treatment at a genome-wide significant level at this first stage. 
Second-stage meta-analysis 
We selected 123 SNPs from 83 loci with P<1x10
-4
 in the first stage meta-analysis for further 
investigation in the second stage, which included 10,951 statin-treated individuals from two RCTs 
and two observational studies (Supplementary Note 3 and Supplementary Tables 1 and 2). The 
second stage meta-analysis confirmed the significant association between genetic variants within 
the CETP loci and HDL-C response from the first stage meta-analysis (rs247616: MAF=0.327, β=0.005, 
SE=0.001, P=1.59x10
-5
) as P<6x10
-4
, the Bonferroni p-value threshold for testing 123 SNPs (Table 1, 
Figure 2, and Supplementary Table 5). The combined effect from the first and second stage meta-
analysis for the CETP rs247616 SNP was genome-wide significant (MAF=0.326, β=0.007, SE=0.001, 
P=8.52x10
-13
) (Table 1, Figure 2, and Supplementary Table 5). No other locus reached statistical 
significance (P<4x10
-4
) in the second stage meta-analysis or in the combined meta-analysis (P<5x10
-
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8
) for association with HDL-C response to statin treatment (Figure 1 and Supplementary Table 5). 
Indeed, Supplementary Table 5 (ordered by the combined meta-analysis p-values) shows that the 
three SNPs within CETP which were genome-wide significant in the first stage, were the only SNPs 
that reached Bonferroni significance in the second stage and genome-wide significance in the 
combined meta-analysis 
Interaction analysis 
To exclude the possibility of confounding in the association between CETP and HDL-C response to 
statin treatment, two analyses were performed. First the main analysis for the CETP SNP rs247616 
was repeated in the placebo users using data from five of the participating RCTs. In addition, in the 
same studies we tested for interaction between the CETP lead SNP rs247616 and randomized statin 
or placebo allocation. Supplementary Figure 2 shows the results for the association between HDL-C 
change during follow-up and rs247616 stratified for placebo and statin users. Table 2 shows a 
significant P-value for interaction in the meta-analysis combining the five studies (P-3.52x10
-3
, 
β=0.007, SE=0.002) for the CETP SNP, indicating that genetic effects of CETP on baseline HDL-C 
contribute at most only in part to genetic effects on HDL-C response in the statin-treated group, as 
the genetic effect is modified by the use of statin treatment.  
Effect of genetic determinants of HDL-C levels on statin-induced HDL-C response 
SNPs previously shown to be associated with HDL-C levels (n=78)[11] were assessed for their 
association with statin-induced HDL-C response in our meta-analysis. After Bonferroni correction, 
rs3764261 (CETP) was the sole genetic variant associated with statin-induced HDL-C response 
amongst the 78 examined variants (Supplementary Table 5). Joint analysis of the HDL-C associated 
variants demonstrated that predisposition to high HDL-C levels is associated with increased statin-
induced HDL-C response (Figure 4). This amounted to a 2.9% fractional increase (β=0.029, SE=0.003, 
P=1x10
-19
) in statin-induced HDL-C response per SD increase in genetically raised HDL-C levels. 
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Excluding the CETP SNP (rs3764261) from the model did not materially change the results (β=0.029, 
SE=0.005, P=1x10
-8
). Testing for heterogeneity did not reveal any indication of pleiotropic 
effects(P=0.64).  
Conditional analysis 
The conditional analysis within GCTA resulted in only one remaining SNP selected in the model, 
namely the lead SNP rs247616 within the CETP locus, with a joint p-value of 9.96x10
-10
 and joint 
β=0.0104, equal to its unconditional effect size estimate. As can be seen from the locus zoom plot in 
Figure 3, the other two genome-wide significant hits are in high LD with the lead SNP, and after 
conditioning on the lead SNP, the GCTA conditional analysis results show that no other SNPs within 
chromosome 16 have significant residual association, with the minimum conditional p-value being 
p~3x10
-5
. Hence we conclude that there is only one independent signal within the CETP association. 
Variance explained 
From genome-wide data of the ASCOT-UK datasets, the trait heritability for HDL-C response to 
statins was estimated as h
2
 = 17.8% (SE = 0.154) although this was non-significant (p=0.125). There 
was insufficient power to run the GCTA analysis in the CARDS dataset, due to smaller sample size. 
The trait variance explained by the lead CETP SNP rs247616 alone was calculated to be 0.04% from 
ASCOT-UK and 0.01% from CARDS, both non-significant (p=0.38 and p=0.54, respectively). 
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Discussion 
In this study we have performed a meta-analysis of GWAS including over 27,700 statin-treated 
individuals, investigating genetic variants associated with variation in HDL-C response to statin 
treatment. We identified three genetic variants in the CETP locus that were highly significantly 
associated with a larger HDL-C response to statin treatment. No other SNPs met the genome-wide 
criterion for association of HDL-C change with statin use. 
CETP plays an important role in HDL-C metabolism by promoting the exchange of cholesteryl esters 
in HDL particles with triglycerides in apolipoprotein B-containing particles, leading to increased HDL 
catabolism and lower HDL-C levels. Increases in HDL-C levels after statin treatment are probably 
partly the result of a reduction in CETP mediated lipid transfer[25], as was also shown in mice 
expressing human CETP.[26]  Statin treatment decreases CETP activity up to 30%.[27 ,28] Previously 
it has been shown that genetic variants within CETP are associated with differences in CETP 
concentration.[29] The three SNPs associated with HDL-C response to statins in the present study 
are located 2.5-7 kb upstream of the CETP gene and are in high linkage disequilibrium (Figure 3).[30] 
The minor alleles of these SNPs have been shown to be associated with lower CETP mRNA 
expression levels in liver tissue and with higher HDL-C levels.[30 ,31]  
Previous studies investigating the association between SNPs in the CETP locus and the  HDL-C 
response to statin treatment have yielded inconsistent results. Several studies showed associations 
with a greater HDL-C response [8 ,10], whereas others showed no significant associations.[12 ,32-34] 
These discrepancies could be explained by limited sample sizes and by the investigation of different 
genetic variants in these studies. An alternative explanation could be the fact that the effect of 
statins on HDL-C response is relatively small and depends on statin dose and type.[3 ,4] Since the 
power to detect genetic effects on these small variations is low in single studies, the results from the 
present large meta-analysis, with replication, provide strong evidence that genetic variation at the 
CETP locus is associated with HDL-C response. 
Page 14 of 66
https://mc.manuscriptcentral.com/jmedgenet
Journal of Medical Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
16 
 
The results of six randomized clinical trials and ten observational studies were combined in the first 
stage of the current study. Different statins were investigated in the trials and used within the 
observational studies, resulting in combining several types of statins in our analysis. This and the 
variation in statin dosages during follow-up for an individual are a limitation of the current study, 
since the pharmacogenetic impact might be dependent on specific statin types and dose. To address 
this possible limitation, the individual study analyses were adjusted for statin equivalent dose based 
on effect on LDL-C levels, making the different statin types likely more comparable with respect to 
clinical effectiveness on HDL-C levels. Combining RCTs and observational cohort might also result in 
heterogeneity between the study types. To reduce the possibility of large heterogeneity we aimed to 
mimic the design of a RCT in the observational studies, by including only new statin-users. 
Comparing heterogeneity of the RCTs and observational studies included in the first stage showed 
no evidence of large heterogeneity (p=0.761, data not shown). 
Another possible limitation of the current study is the association of the identified genetic variant 
with baseline HDL-C concentration. As shown in previous large GWAS studies, the CETP SNP 
rs3764261 is strongly associated with HDL-C levels.[11 ,31] In pharmacogenetic studies investigating 
lipid responses to drug exposure, it is important to eliminate the effect of the association between 
baseline lipid levels and the investigated genetic variants.[13] To reduce the impact of these possible 
confounding effects, our response to treatment analyses were adjusted for baseline HDL-C levels. In 
addition, interaction analyses in five of the RCTs, with direct modeled comparison with a random 
assignment to a placebo group, suggested little or no influence of the association between the CETP 
SNPs and baseline HDL-C levels on the genetic effect on HDL-C response to statin treatment. It is, 
however, possible that mechanisms underlying the effects of CETP on HDL-C levels are also involved 
in mediating statin effects on HDL-C. 
All genetic data in the current study was imputed to up to 2.5 million autosomal SNPs based on data 
from the HapMap project.[15] In addition, in our analysis we excluded genetic variants with a minor 
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allele frequency <1%, restricting our analysis to common genetic variants. Imputation based on the 
more recent 1000 Genomes project could reveal more associations with rare genetic variants.[35] 
Future studies using exome sequencing data and investigating rare variants may identify additional 
associations between genetic variants and statin-induced HDL-C response. However, the non-
significant estimate of heritability attributable to common variation in our analysis may indicate that 
the observed increase in HDL-C levels after statin-treatment may be mainly due to environmental 
rather than genetic effects. 
The implications of the present findings regarding genetic effects on the efficacy of statins for 
reductions in risk of CVD are uncertain. Based on the strong inverse relationship of HDL-C with CVD, 
the greater statin-induced increase in HDL-C among carriers of the minor vs. major alleles of the 
three CETP SNPs reported here may confer a greater protective effect of statins on CVD in patients 
carrying the minor allele. However, a recent study employing Mendelian randomization found that 
genotypes associated with plasma HDL-C levels were not associated with the impact on CVD risk that 
would be predicted by the magnitude of the genotypic effects on HDL-C.[7] Moreover, two large 
clinical trials have failed to show reduction of CVD events by nicotinic acid-induced increases in HDL-
C in patients with well-controlled LDL-C levels.[36 ,37] Hence, whether greater genetically-mediated 
HDL-C increases with statin treatment confer increased protection from CVD remains unknown. 
In conclusion, this study is the largest meta-analysis of GWAS for HDL-C response to statin treatment 
conducted to date. The findings suggest that CETP may be the only locus in which common genetic 
variants are significantly associated with a substantial HDL-C response to statin treatment in 
individuals of European descent.  
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Figure legends 
Figure 1. Results of the GWAS meta-analysis. Manhattan plot presenting the –log10 P-values from the 
combined stage 1 and 2 meta-analysis on HDL-C response to statin treatment. The top (red) line 
represents the genome-wide significant P-value 5x10
-8
, the second (blue) line represents the P-value 
1x10
-4
, the threshold used for selecting SNPs to take forward to the second stage. Hence the results 
of these SNPs come from the lager combined meta-analysis, whereas all other results are taken from 
the stage 1 discovery meta-analysis. 
Figure 2. Forest plot showing the association in each study and overall  association of the lead CETP 
SNP rs247616 with HDL-C response to statin treatment. Beta represents fractional HDL-C change for 
each copy of the minor allele. 
Figure 3. Regional association plot of the CETP region that was genome-wide significant for 
association with HDL-C response to statin treatment, using the results of the combined meta-
analysis (generated using LocusZoom [39]). The color of each SNP is based on the LD (r
2
) with the 
lead SNP rs247616 (shown in purple). The RefSeq genes in the region are shown in the lower panel. 
Figure 4. Plot of the per-allele association of genetic variants with HDL-C levels (x-axis, per allele in 
SD units, as reported by Willer et al. [11]) against the association with HDL-C response to statin 
treatment (y-axis, percentage) (generated using [22]). The regression line shows the linear 
relationship between these two variables, with 95% confidence boundaries. 
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Table 1. Association of CETP SNP rs247616 (chromosome 16, bp 55547091) with HDL-C response after statin treatment in the stage 1, stage 2, and 
combined GWAS meta-analyses. 
Phase N Coding allele Non-coding allele Frequency coding allele Beta* SE % extra increase
# 
P-value 
Stage 1 14693 T C 0.324 0.011 0.002 1.1 5.95x10
-10 
Stage 2 10961 T C 0.327 0.005 0.001 0.5 1.59x10
-5 
Combined 25654 T C 0.326 0.007 0.001 0.7 8.52x10
-13 
*Beta for difference between the natural log transformed on- and off-treatment HDL-C levels, adjusted for natural log transformed off-treatment HDL-C, 
age, sex, and study specific covariates. The beta reflects the fraction of differential HDL-C lowering in carriers vs. non-carriers of the SNP; a positive beta 
indicates a better statin response (larger HDL-C increase). 
#
This percentage reflects the % extra HDL-C increase in carriers vs. non-carriers of the SNP. 
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Table 2. Interaction between CETP rs247616 and statin vs. placebo allocation on HDL-C response. Meta-analysis of data from 5 RCTs. 
SNP N Coding allele Non-coding allele Frequency coding allele Interaction 
Beta 
Interaction SE Interaction P-value 
rs247616 17857 T C 0.341 0.007 0.002 3.52x10
-3 
Interaction beta and SE refer to statistics from linear regression modelling the difference between the natural log transformed on- and of-treatment HDL-C 
levels adjusted for natural log transformed off-treatment HDL-C, age, sex, and study specific covariates, and including an interaction term between SNP and 
statin or placebo allocation. The interaction p-value refers to the significance of the SNP-by-statin or placebo allocation interaction term in the regression 
model. 
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Figure 1. Results of the GWAS meta-analysis. Manhattan plot presenting the –log10 P-values from the 
combined stage 1 and 2 meta-analysis on HDL-C response to statin treatment. The top (red) line represents 
the genome-wide significant P-value 5x10-8, the second (blue) line represents the P-value 1x10-4, the 
threshold used for selecting SNPs to take forward to the second stage. Hence the results of these SNPs 
come from the lager combined meta-analysis, whereas all other results are taken from the stage 1 discovery 
meta-analysis.  
Figure 1  
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Figure 2. Forest plot showing the association in each study and overall  association of the lead CETP SNP 
rs247616 with HDL-C response to statin treatment. Beta represents fractional HDL-C change for each copy 
of the minor allele.  
Figure 2  
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Figure 3. Regional association plot of the CETP region that was genome-wide significant for association with 
HDL-C response to statin treatment, using the results of the combined meta-analysis (generated using 
LocusZoom [39]). The color of each SNP is based on the LD (r2) with the lead SNP rs247616 (shown in 
purple). The RefSeq genes in the region are shown in the lower panel.  
Figure 3  
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Figure 4. Plot of the per-allele association of genetic variants with HDL-C levels (x-axis, per allele in SD 
units, as reported by Willer et al. [11]) against the association with HDL-C response to statin treatment (y-
axis, percentage) (generated using [22]). The regression line shows the linear relationship between these 
two variables, with 95% confidence boundaries.  
Figure 4  
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Supplementary Table 1: Participating study characteristics of the statin users only. 
Study sample Participants Male,  
N (%) 
Age*, 
mean ± SD 
Age*, range Body mass index, 
kg/m
2
, mean ± SD 
Diabetes, 
N (%) 
Hypertension, N 
(%) 
Randomized controlled trials N Overall       
PROSPER 2550 1228 (48) 75.4 (3.4) 70.2-83.3 26.8 (4.1) 256 (10.0) 1592 (62.4) 
ASCOT UK 978 864 (88) 64.0 (8.1) 41.0-90.0 29.1 (5.1) 215 (22.0) 978 (100.0) 
CARDS 1194  632 (53) 61.6 (8.2) 40-76 28.7 (3.6) 1194 (100)  1038 (87) 
PRINCE 1348 1040 (77.2) 64.8 (13.0) 26-100 29.0 (5.3) 271 (20.1) 551 (40.9) † 
CAP 591 312 (52.8) 54.5 (12.6) 30-88 27.7 (5.5) 21 (3.6) ‡ 108 (18.3) † 
TNT 1845 1521 (82.4) 62.4 (8.4) 36.4-76.0 29.1 (4.7) 411 (22.3) 631 (34.2) 
Observational studies N Overall       
AGES 281 123 (43.8) 74.4 (4.8) 66-92 27.5 (4.1) 58 (20.6) 237 (84.3) 
ARIC 1163 601 (52) 55 (5.3) 45-64 27.7 (4.6) 172 (14.8) 434 (37.6) 
ASCOT UK  1067 894 (84) 63.4 (8.0) 40.0-80.0 29.1 (4.7) 244 (22.9) 1067 (100.0) 
BioVU 435 231(53) 67.0 (14.5) 21-99 29.1 (5.8) 119 (27.4) 412 (94.7) 
CHS 315 117 (37.1) 69.5 (3.1)** 65-87 26.6 (4.2) 23 (7.3) 91 (28.9) 
FHS 1395 774 (55.5) 57 (9.9) 23-85 28.7 (5.1) 205 (14.7) 477 (34.2) 
Health ABC 310 175 (56%) 73.4 (2.7) 69 - 80 27.2 (4.1) 60 (19%) 183 (59%) 
HVH 1896 789 (41.6) 66.3 (9.5)** 32-89 31.0 (6.7) 428 (22.6) 1431 (75.5) 
MESA 360 180 (50.0) 66.9 (9.3) 47-87 28.9 (5.4) 48 (13.4) 191 (53.1) 
Rotterdam Study I 744 351 (47.2) 63.2 (5.0) 55.0-81.5 27.4 (3.9) 110 (14.8) 234 (31.5) 
Rotterdam Study II 297 166 (55.9) 62.2 (5.5) 55.2-86.5 28.1 (3.9) 53 (17.8) 120 (41.0) 
Second stage studies N Overall       
ASCOT Scandinavia RCT 725 575 (79) 61.0 (8.8) 40.0-80.0 28.6 (5.0) 156 (21.5) 725 (100.0) 
ASCOT Scandinavia observational 611 447 (73) 60.3 (8.5) 40.0-79.0 28.6 (4.2) 124 (20.3) 611 (100.0) 
GoDARTS 6133 4293 (70) 66.0 (11.2) 40-95 30.6 (5.3) 6133 (100) NA 
JUPITER 3417 2346 (69) 65.9 (7.6) 50-93 29.5 (5.7) 12 (0.3) 1900 (55.6) 
*Age at DNA collection 
** Age at baseline 
†Defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg. 
‡Defined as fasting glucose ≥126 mg/dl (diabetes on treatment were excluded from the trial). 
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Supplementary Table 2: High-density lipoprotein characteristics of the statin users only. 
Study sample Participants Type of statin Statin dose 
(mg/day) 
HDL-C off-treatment 
(mmol/L) 
Mean ± SD 
HDL-C on-treatment 
(mmol/L)* 
Mean ± SD 
Follow-up time 
(months) 
Mean ± SD 
RCTs N Overall      
PROSPER 2550 Pravastatin 40 1.29 (0.36) 1.40 (0.38) 29.5 (9.2) 
ASCOT UK 978 Atorvastatin 10 1.27 (0.33) 1.27 (0.33) First year used 
CARDS 1194 Atorvastatin 10 1.39 (0.31) 1.42 (0.39) 46.8 (4.7) 
PRINCE 1348 Pravastatin 40 0.94 (0.26) 0.99 (0.27) 12 weeks 
CAP 591 Simvastatin 40 1.38 (0.42) 1.44 (0.45) 6 weeks 
TNT 1845 Atorvastatin 10 1.20 (0.26) 1.17 (0.26) 2.0 (0.2) 
Observational studies N Overall      
AGES 281 mixed mixed 1.51 (0.42) 1.53 (0.44) 61.8 (2.5) 
ARIC 1163 A, Ce, F, L, P, S, Ch Not available 1.13 (0.34) 1.17 (0.34) 36.1 (3.1) 
ASCOT UK 1067 A (N=775), F (N=9), P (N=28), 
R (N=11), S (N=244) 
12.4 (7.5), 28.9 (20.3), 28.9 (12.2), 
14.1 (9.7), 28.6 (14.0) 
1.24 (0.33) 1.33 (0.35) 11.7 (4.3) 
BioVU 435 A, S, F, P, L, R 5,10,20,40,80 1.29 (0.43) 1.29 (0.39) 108.6 (46.0)
1 
CHS 315 A, P, L, S, F, Ce 14.1 (8.5), 20.8 (9.3), 21.4 (8.9), 16.5 
(10.6), 35.0 (23.7), 0.37 (0.08) 
1.36 (0.34) 1.34 (0.36) 43.4 (43.2)
2
 
FHS 1395 mixed mixed 1.21 (0.36) 1.30 (0.38) 63.6 (22.8) 
Health ABC 310 mixed mixed 1.28 (0.37) 1.32 (0.37) 51.17 (17.22) 
HVH 1896 A, P, L, S, R 34.6 (24.0), 20.8 (4.9), 33.5 (9.8), 36.7 
(15.2), 20.0 
1.31 (0.40) 1.33 (0.41) 3.6 (5.0)
2 
MESA 360 mixed mixed 1.30 (0.36) 1.35 (0.41) 19.9 (3.2) 
Rotterdam Study I 744 S (N=430), P (N=88), F (N=54),  
A (N=158), R (N=14) 
18.3 (10.6), 21.8 (11.4), 33.3 (17.8), 
16.6 (9.3), 7.9 (4.3) 
1.30 (0.30) 1.40 (0.40) 71.4 (11.0)
3 
125.1 (53.7)
4 
Rotterdam Study II 297 S (N=166), P (N=32), F (N=7),  
A (N=70), R (N=22) 
20.7 (6.3), 31.3 (11.8), 62.9 (49.6), 
17.6 (9.8), 9.3 (4.2) 
1.30 (0.30) 1.40 (0.30) 64.6 (14.7)
3 
92.7 (38.5)
4 
Second stage studies N Overall      
ASCOT SC RCT 725 Atorvastatin 10 1.33 (0.38) 1.32 (0.36) First year used 
ASCOT SC observational 611 A (N=458), F (N=11), L (N=4), 
R (N=12), S (N=126) 
13.4 (8.3), 56.4 (23.4), 40.0 (28.3), 
10.1 (4.3), 25.4 (14.0) 
1.27 (0.37) 1.33 (0.38) 10.8 (4.3) 
GoDARTS 6133 mixed mixed 1.33 (0.35) 1.44 (0.38) 49.6 (12) 
JUPITER 3417 Rosuvastatin 20 1.40 (0.40) 1.44 (0.42) 12 months 
*Mean of multiple on-treatment measurements 
1
Median HDL within 18 months after treatment used for analysis. 
2
Case-Control and cohort studies - time listed is time from statin initiation to HDL measurement. 
3
Mean 
time between off- and on-treatment HDL-C measurement. 
4
Mean
 
time between start RS and on-treatment HDL-C measurement. 
Abbreviations: A, Atorvastatin; Ce, Cerivastatin; F, Fluvastatin; L, Lovastatin; P, Pravastatin; S, Simvastatin; Ch, Cholestin; R, Rosuvastatin
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Supplementary Table 3: Genotyping characteristics 
Study sample Participants Genotyping platform Calling algorithm NCBI build Imputation 
software 
Analysis 
software 
Exclusion criteria used 
RCTs N Overall       
PROSPER 2550 Illumina Human  
660_Quadv1 
Beadstudio 36.22 MACH v1.0 16 ProbABEL Sample call rate>=97.5%, SNP call rate >=98%, SNP 
MAF>0.01 
ASCOT UK 978 Illumina Human 370CNV Beadstudio 36.22 MACH v1.0 16 ProbABEL Sample call rate <=95%, SNP call rate <=97%, 
HWE<=10E-7, relatedness 
CARDS 1194 Perlegen 6 Perlegen 6 36.22 Impute2 SNPTEST Sample call rate>=98% 
SNP call rate>=98% 
MAF>0.01 
PRINCE 1348 Illumina Human 317K 
and 610_Quad 
Illumina 36.23 Bimbam v0.99 SNPTEST Imputation information>0.30, SNP MAF>0.01 
CAP 591 Illumina Human 317K 
and 610_Quad 
Illumina 36.23 Bimbam v0.99 SNPTEST Imputation information>0.30, SNP MAF>0.01 
TNT 1845 Perlegen 322K Perlegen 36.3 IMPUTE 2 
v2.1.0,  
GTOOL v 0.6.6 
Plink v 
1.07 
Sample call rate>=98%, 
SNP call rate >=98% 
Observational  N Overall       
AGES 281 Illumina HU370CNV Beadstudio 36 MACH v1.0 16 ProbABEL Pre imputation exclusions: MAF >0.01, HWE p 10-6, 
callrate 0.97. Call rate 0.95 
ARIC 1163 Affymetrix 6.0 Birdseed 36 MACH v1.0.16 ProbABEL MAF <1%, call rate <95%, HWE<10E-5 
ASCOT UK 1067 Illumina Human 370CNV Beadstudio 36.22 MACH v1.0 16 ProbABEL Sample call rate <=95%, SNP call rate <=97%, 
HWE<=10E-7, relatedness 
BioVu 435 Illumina 660K, 
Illumina OMNI 
Illumina 36(660K), 
37.1(OMNI) 
MACH v1.0.16 R Sample call rate>=98%, SNP call rate >=98%, SNP 
MAF>0.01 
CHS 315 Illumina Human 370CNV BeadStudio 36 BIMBAM R Samples excluded for sex mismatch, discordance 
with prior genotyping, or call rate < 95% 
SNPs excluded for: call rate < 97%, HWE P < 10-5, > 
2 duplicate errors or Mendelian inconsistencies (for 
reference CEPH trios), heterozygote frequency = 0, 
SNP not found in HapMap.  
FHS 1395 Affymetrix 250K Sty, 
250K Nsp & MIPS 50K 
BRLMM 36.22 MACH v1.0.15 R 2.6.1 
with 
Sample call rate ≤ 97%, 
SNP call rate ≤ 95%, SNP >1000 Mendelian errors, 
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Study sample Participants Genotyping platform Calling algorithm NCBI build Imputation 
software 
Analysis 
software 
Exclusion criteria used 
Gene Centric lmekin Heterozygosity 5 SD from Mean (<25.758% or 
>29.958%) 
Health ABC 310 Illumina Human1M-Duo 
BeadChip 
BeadStudio 36.22 MACH v1.0.16 R Sample call rate>=97%, SNP call rate >=97%, SNP 
MAF>0.01 
HVH 1896 Illumina Human 370CNV BeadStudio 36 BIMBAM R Samples excluded for sex mismatch or call rate < 
95%. SNP exclusions: call rate < 97%, HWE P < 10
-5
, 
> 2 duplicate errors or Mendelian inconsistencies 
(for reference CEPH trios), heterozygote frequency 
= 0, SNP not found in HapMap, inconsistencies 
across genotyping batches. 
MESA 360 Affymetrix Genome-
Wide Human SNP Array 
6.0 
Affymetrix 36.24 IMPUTE v2.1.0 SNPTEST  SNP call rate >=95%, Imputation information>0.30, 
SNP MAF>0.01 
Rotterdam Study 1041 Illumina HumanHap 
550K 
Illumina 
GenomeStudio 
36.22 MACH v1.0.15 ProbABEL Call rate <98%, HWE  
P<10
-6
, or MAF<1%  
Second stage        
ASCOT SC  RCT: 725 
OBS: 611 
Illumina Human Omni 
Exome Express v8.1 
BeadStudio, 
followed by zCall 
37 MACH v1.0.18 R GWAS: Exclude samples with: Discrepant sex, 
repeat samples, <95% genotyping success rate. 
Excluded SNPs with: <0.5% MAF, <95% call rate, 
HWE p<5x10
-7 
GoDARTS 6133 Affymatrix 6.0, Human 
Omni Express 
CHIAMO, 
Illumina 
37 IMPUTE SNPTEST Standard GWAS criteria 
JUPITER 3417 Illumina Omni Quad 1M Illumina 
GenomeStudio  
36 MACH v1.0.16 R Sample call rate < 90%, SNP call rate <98%  
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Supplementary Table 4: Statin dose adjustments in observational studies, based on a modified 
version of a table in Drugs 1998; 56: Suppl 1: 25-31
1
. 
Statin Dose range 
(mg) 
Typical starting 
dose (PDR) 
Dose % 
equivalent 
Reduction  
LDL (%) 
Reduction  
TC (%) 
Atorvastatin 10-80 10-20 10 35 29 
Cerivastatin 0.2-0.4 0.2-0.3 0.3 30 - 
Fluvastatin 10-80 40 60 31 23 
Lovastatin 10-80 20 40 32 23 
Pravastatin 10-40 40 40 30 25 
Simvastatin 10-80 20-40 20 36 28 
Rosuvastatin 5-40 10 5 45 33 
Pitavastatin 2-4 2 2 37 - 
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Supplementary table 5: First stage, second stage, and combined results of all SNPs investigated in the second stage. 
     
Stage 1 
 
Stage 2 
 
Combined 
SNP CHR position A1 A2 Freq A1 Beta* SE P-value N 
 
Freq A1 Beta* SE P-value N 
 
Freq A1 Beta* StdErr P-value N 
rs247616 16 55,547,091 t c 0.324 0.0106 0.0017 5.95E-10 14693 
 
0.327 0.0053 0.0012 1.59E-05 10961 
 
0.326 0.0071 0.0010 8.52E-13 25654 
rs3764261 16 55,550,825 a c 0.324 0.0105 0.0017 8.61E-10 14695 
 
0.330 0.0053 0.0012 1.28E-05 10990 
 
0.328 0.0071 0.0010 8.82E-13 25685 
rs173539 16 55,545,545 t c 0.326 0.0105 0.0018 6.94E-09 14161 
 
0.325 0.0054 0.0012 1.48E-05 10814 
 
0.325 0.0071 0.0010 5.90E-12 24975 
rs12916361 15 79,025,100 t c 0.912 0.0143 0.0032 9.10E-06 14318 
 
0.931 0.0102 0.0103 3.24E-01 4854 
 
0.914 0.0139 0.0031 5.11E-06 19172 
rs5112 19 50,122,120 c g 0.441 -0.0104 0.0025 3.61E-05 12805 
 
0.451 -0.0089 0.0081 2.74E-01 1331 
 
0.442 -0.0103 0.0024 1.73E-05 14136 
rs1445311 12 33,171,126 t c 0.933 -0.0116 0.0028 3.89E-05 16520 
 
0.935 -0.0046 0.0023 4.24E-02 11063 
 
0.934 -0.0074 0.0018 2.89E-05 27583 
rs7973897 12 33,173,955 t c 0.936 -0.0119 0.0029 4.61E-05 16524 
 
0.935 -0.0045 0.0023 4.63E-02 11063 
 
0.935 -0.0073 0.0018 4.15E-05 27587 
rs17330251 4 94,500,553 t g 0.082 -0.0136 0.0031 1.32E-05 12774 
 
0.081 -0.0039 0.0027 1.48E-01 7933 
 
0.082 -0.0080 0.0020 7.64E-05 20707 
rs1560694 19 6,218,827 a g 0.403 0.0066 0.0016 4.20E-05 14641 
 
0.411 0.0020 0.0011 7.42E-02 11049 
 
0.409 0.0036 0.0009 1.22E-04 25690 
rs9912353 17 53,222,039 a c 0.859 0.0095 0.0024 8.47E-05 14696 
 
0.864 0.0034 0.0021 1.06E-01 7986 
 
0.861 0.0061 0.0016 1.28E-04 22682 
rs3751413 13 112,902,716 t c 0.796 0.0086 0.0021 4.77E-05 12758 
 
0.766 0.0019 0.0036 6.03E-01 4854 
 
0.788 0.0069 0.0018 1.39E-04 17612 
rs7557776 2 33,431,296 a g 0.072 -0.0128 0.0032 7.13E-05 14695 
 
0.060 -0.0041 0.0025 9.18E-02 10848 
 
0.064 -0.0074 0.0020 1.61E-04 25543 
rs1378394 3 35,450,087 t c 0.924 0.0119 0.0029 4.61E-05 14697 
 
0.933 0.0035 0.0023 1.17E-01 11018 
 
0.929 0.0067 0.0018 1.73E-04 25715 
rs12421631 11 100,709,979 a g 0.688 -0.0071 0.0018 8.97E-05 14603 
 
0.653 -0.0019 0.0031 5.46E-01 4854 
 
0.679 -0.0058 0.0016 1.97E-04 19457 
rs6424961 1 182,875,556 a t 0.957 0.0297 0.0072 4.20E-05 10268 
 
0.946 0.0059 0.0093 5.23E-01 4854 
 
0.953 0.0208 0.0057 2.58E-04 15122 
rs1186925 5 57,230,380 t g 0.058 -0.0164 0.0041 7.13E-05 12758 
 
0.013 -0.0033 0.0057 5.65E-01 7202 
 
0.043 -0.0119 0.0033 3.40E-04 19960 
rs10132919 14 55,013,890 t c 0.884 -0.0106 0.0025 2.55E-05 14695 
 
0.889 -0.0024 0.0018 1.73E-01 11051 
 
0.887 -0.0052 0.0015 3.43E-04 25746 
rs17577246 4 68,420,188 a g 0.204 -0.0089 0.0020 9.92E-06 14694 
 
0.184 -0.0011 0.0021 6.05E-01 7679 
 
0.194 -0.0051 0.0014 3.64E-04 22373 
rs17116225 15 23,617,694 t c 0.962 0.0225 0.0047 2.00E-06 12758 
 
0.967 0.0032 0.0033 3.36E-01 7495 
 
0.965 0.0097 0.0027 3.74E-04 20253 
rs243874 20 13,019,871 a c 0.242 0.0100 0.0023 1.58E-05 14562 
 
0.259 -0.0017 0.0040 6.69E-01 4854 
 
0.246 0.0071 0.0020 3.74E-04 19416 
rs2791634 2 125,426,327 a c 0.478 0.0076 0.0017 9.03E-06 12757 
 
0.485 0.0015 0.0011 1.87E-01 11038 
 
0.483 0.0033 0.0009 3.74E-04 23795 
rs2595427 11 6,808,473 a t 0.721 -0.0077 0.0019 5.72E-05 14693 
 
0.714 0.0001 0.0035 9.85E-01 4854 
 
0.720 -0.0059 0.0017 3.89E-04 19547 
rs1229470 7 81,381,822 a g 0.134 0.0121 0.0030 6.20E-05 11120 
 
0.147 0.0032 0.0020 1.22E-01 7986 
 
0.143 0.0060 0.0017 3.92E-04 19106 
rs2602647 2 125,380,491 a g 0.486 0.0076 0.0017 9.03E-06 12758 
 
0.478 0.0014 0.0011 2.09E-01 10958 
 
0.481 0.0033 0.0009 4.42E-04 23716 
rs11834039 12 41,320,636 t g 0.161 -0.0087 0.0021 3.89E-05 14697 
 
0.161 -0.0020 0.0015 1.92E-01 11058 
 
0.161 -0.0043 0.0012 5.02E-04 25755 
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Stage 1 
 
Stage 2 
 
Combined 
SNP CHR position A1 A2 Freq A1 Beta* SE P-value N 
 
Freq A1 Beta* SE P-value N 
 
Freq A1 Beta* StdErr P-value N 
rs17033144 3 35,427,890 a g 0.078 -0.0122 0.0030 5.39E-05 14696 
 
0.065 -0.0028 0.0023 2.20E-01 11035 
 
0.070 -0.0063 0.0018 5.57E-04 25731 
rs6952465 7 150,522,574 a g 0.957 -0.0174 0.0043 5.87E-05 10493 
 
0.957 -0.0039 0.0037 2.94E-01 7986 
 
0.957 -0.0096 0.0028 6.01E-04 18479 
rs12861586 13 41,808,464 a c 0.090 -0.0128 0.0031 4.13E-05 12433 
 
0.089 -0.0028 0.0020 1.63E-01 10805 
 
0.090 -0.0058 0.0017 6.08E-04 23238 
rs11181609 12 41,325,764 t c 0.841 0.0091 0.0022 4.00E-05 14697 
 
0.839 0.0020 0.0015 1.96E-01 11043 
 
0.839 0.0043 0.0012 6.49E-04 25740 
rs946066 14 55,002,625 a c 0.117 0.0108 0.0025 1.79E-05 14689 
 
0.109 0.0018 0.0018 3.12E-01 11038 
 
0.112 0.0049 0.0015 7.81E-04 25727 
rs302567 6 39,759,450 a g 0.064 0.0123 0.0029 2.54E-05 16536 
 
0.056 0.0020 0.0024 4.06E-01 11061 
 
0.059 0.0062 0.0019 8.19E-04 27597 
rs2446644 6 39,734,657 a t 0.064 0.0123 0.0029 2.54E-05 16530 
 
0.056 0.0019 0.0024 4.19E-01 11063 
 
0.059 0.0062 0.0018 8.74E-04 27593 
rs6552126 4 68,421,259 t g 0.792 0.0085 0.0019 8.90E-06 14697 
 
0.805 0.0002 0.0020 9.30E-01 7767 
 
0.798 0.0046 0.0014 9.24E-04 22464 
rs11886534 2 3,815,178 a g 0.570 0.0063 0.0016 9.23E-05 14636 
 
0.575 0.0014 0.0011 2.26E-01 11021 
 
0.573 0.0031 0.0009 1.05E-03 25657 
rs7130440 11 110,922,989 a g 0.627 -0.0069 0.0017 5.57E-05 12758 
 
0.638 -0.0014 0.0012 2.39E-01 10947 
 
0.634 -0.0032 0.0010 1.05E-03 23705 
rs12283768 11 74,130,306 t g 0.037 0.0156 0.0039 7.13E-05 16509 
 
0.034 0.0031 0.0031 3.26E-01 11026 
 
0.035 0.0080 0.0024 1.09E-03 27535 
rs17507421 2 3,815,450 a g 0.582 0.0063 0.0016 9.23E-05 14639 
 
0.582 0.0014 0.0011 2.37E-01 11008 
 
0.582 0.0030 0.0009 1.13E-03 25647 
rs4906637 15 23,643,990 t c 0.945 0.0156 0.0038 4.57E-05 14160 
 
0.944 0.0029 0.0025 2.42E-01 10985 
 
0.944 0.0067 0.0021 1.23E-03 25145 
rs1444212 3 3,875,591 a g 0.636 -0.0071 0.0016 1.05E-05 14643 
 
0.641 -0.0009 0.0012 4.57E-01 11049 
 
0.639 -0.0030 0.0009 1.29E-03 25692 
rs10134660 14 88,578,272 t c 0.806 -0.0076 0.0019 7.13E-05 14697 
 
0.791 -0.0014 0.0014 2.96E-01 11043 
 
0.796 -0.0036 0.0011 1.38E-03 25740 
rs13355303 5 100,939,572 t c 0.782 -0.0081 0.0020 5.78E-05 14670 
 
0.802 -0.0014 0.0014 3.11E-01 11061 
 
0.796 -0.0037 0.0012 1.55E-03 25731 
rs17274136 4 94,610,507 a g 0.161 -0.0100 0.0023 1.58E-05 14642 
 
0.135 -0.0005 0.0022 8.15E-01 7826 
 
0.147 -0.0049 0.0016 1.66E-03 22468 
rs12500707 4 183,396,389 a g 0.327 -0.0079 0.0019 3.65E-05 12175 
 
0.329 -0.0009 0.0016 5.75E-01 7930 
 
0.328 -0.0038 0.0012 1.87E-03 20105 
rs897266 8 13,269,177 a g 0.582 0.0059 0.0014 2.85E-05 16483 
 
0.582 0.0006 0.0011 5.87E-01 11021 
 
0.582 0.0027 0.0009 2.04E-03 27504 
rs12290339 11 74,138,810 a g 0.031 0.0176 0.0044 7.13E-05 16514 
 
0.034 0.0029 0.0031 3.52E-01 11040 
 
0.033 0.0078 0.0025 2.17E-03 27554 
rs983884 5 146,219,161 t g 0.119 0.0087 0.0021 3.89E-05 16531 
 
0.109 0.0008 0.0018 6.54E-01 11057 
 
0.114 0.0042 0.0014 2.30E-03 27588 
rs11151789 18 68,526,072 a c 0.307 -0.0067 0.0017 9.09E-05 14641 
 
0.305 -0.0011 0.0012 3.77E-01 10930 
 
0.306 -0.0031 0.0010 2.36E-03 25571 
rs11723806 4 26,692,841 c g 0.350 0.0072 0.0018 7.13E-05 14679 
 
0.314 -0.0041 0.0035 2.44E-01 4854 
 
0.342 0.0049 0.0016 2.38E-03 19533 
rs501955 2 134,984,330 a c 0.354 0.0063 0.0016 9.23E-05 14641 
 
0.327 0.0009 0.0012 4.46E-01 10973 
 
0.337 0.0029 0.0010 2.74E-03 25614 
rs13265604 8 13,572,172 t c 0.831 0.0092 0.0022 3.29E-05 14652 
 
0.845 0.0010 0.0016 5.37E-01 10955 
 
0.840 0.0037 0.0013 3.37E-03 25607 
rs622418 9 89,775,863 a g 0.507 -0.0072 0.0017 2.60E-05 12757 
 
0.490 -0.0003 0.0015 8.50E-01 7862 
 
0.497 -0.0032 0.0011 3.78E-03 20619 
rs10518102 4 73,487,738 t g 0.057 -0.0131 0.0033 8.08E-05 14697 
 
0.061 -0.0016 0.0024 4.87E-01 11063 
 
0.060 -0.0055 0.0019 4.04E-03 25760 
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Stage 1 
 
Stage 2 
 
Combined 
SNP CHR position A1 A2 Freq A1 Beta* SE P-value N 
 
Freq A1 Beta* SE P-value N 
 
Freq A1 Beta* StdErr P-value N 
rs8181581 11 20,949,701 t c 0.085 -0.0124 0.0029 2.18E-05 14697 
 
0.083 -0.0010 0.0020 6.18E-01 11051 
 
0.083 -0.0048 0.0017 4.12E-03 25748 
rs13134793 4 181,685,248 t c 0.961 0.0163 0.0041 7.89E-05 14696 
 
0.953 0.0022 0.0027 4.08E-01 11063 
 
0.956 0.0064 0.0022 4.18E-03 25759 
rs2963078 5 146,225,801 t c 0.882 -0.0089 0.0022 5.89E-05 16519 
 
0.890 -0.0007 0.0018 7.13E-01 11063 
 
0.887 -0.0040 0.0014 4.27E-03 27582 
rs7960253 12 128,585,576 t c 0.847 0.0088 0.0022 7.13E-05 14697 
 
0.850 0.0010 0.0016 5.44E-01 11047 
 
0.849 0.0036 0.0013 4.61E-03 25744 
rs9511450 13 24,273,026 a g 0.701 -0.0074 0.0015 9.64E-07 15999 
 
0.720 0.0005 0.0013 6.64E-01 11060 
 
0.712 -0.0027 0.0010 4.73E-03 27059 
rs2335478 7 157,763,026 a g 0.055 0.0175 0.0044 7.83E-05 11290 
 
0.046 0.0022 0.0028 4.41E-01 10728 
 
0.049 0.0066 0.0024 5.23E-03 22018 
rs7074609 10 123,176,624 t c 0.653 0.0069 0.0017 5.57E-05 14643 
 
0.655 0.0007 0.0012 5.69E-01 11057 
 
0.654 0.0027 0.0010 5.38E-03 25700 
rs4909170 7 157,781,459 t c 0.039 0.0169 0.0043 9.51E-05 13504 
 
0.042 0.0020 0.0028 4.83E-01 11057 
 
0.041 0.0064 0.0023 6.26E-03 24561 
rs11626215 14 94,365,382 t c 0.645 -0.0067 0.0017 9.09E-05 14668 
 
0.632 -0.0002 0.0015 9.05E-01 7986 
 
0.637 -0.0030 0.0011 7.33E-03 22654 
rs11025857 11 20,963,785 t g 0.084 -0.0128 0.0030 2.27E-05 14697 
 
0.082 -0.0006 0.0021 7.52E-01 11056 
 
0.083 -0.0045 0.0017 7.52E-03 25753 
rs9507417 13 24,299,909 t c 0.715 -0.0070 0.0015 3.59E-06 16532 
 
0.719 0.0006 0.0013 6.47E-01 11027 
 
0.718 -0.0025 0.0010 8.31E-03 27559 
rs1051942 5 38,971,001 a t 0.172 0.0090 0.0021 2.08E-05 14696 
 
0.169 0.0003 0.0015 8.64E-01 11030 
 
0.170 0.0032 0.0012 8.61E-03 25726 
rs1488455 3 3,844,513 a t 0.334 0.0071 0.0017 3.37E-05 14643 
 
0.331 0.0003 0.0012 8.12E-01 10888 
 
0.332 0.0026 0.0010 8.66E-03 25531 
rs7506639 18 5,819,190 t c 0.344 -0.0074 0.0017 1.54E-05 14641 
 
0.348 -0.0002 0.0012 8.81E-01 10962 
 
0.347 -0.0026 0.0010 8.85E-03 25603 
rs10886934 10 123,170,221 a g 0.247 -0.0075 0.0019 8.87E-05 14163 
 
0.244 -0.0005 0.0013 6.80E-01 11054 
 
0.245 -0.0028 0.0011 9.95E-03 25217 
rs1559474 2 50,766,521 a g 0.220 0.0072 0.0017 2.60E-05 16522 
 
0.237 -0.0001 0.0013 9.39E-01 11051 
 
0.230 0.0027 0.0010 1.10E-02 27573 
rs264011 1 45,233,419 a g 0.573 0.0060 0.0015 7.13E-05 16443 
 
0.578 0.0001 0.0012 9.64E-01 10748 
 
0.576 0.0023 0.0009 1.30E-02 27191 
rs10060696 5 39,044,888 a g 0.834 -0.0087 0.0021 3.89E-05 14697 
 
0.830 -0.0001 0.0015 9.25E-01 11055 
 
0.831 -0.0030 0.0012 1.34E-02 25752 
rs4432938 5 2,157,506 a t 0.476 0.0063 0.0016 9.23E-05 14108 
 
0.473 0.0003 0.0011 8.11E-01 10987 
 
0.474 0.0023 0.0009 1.35E-02 25095 
rs11702628 21 21,205,295 t c 0.514 -0.0065 0.0016 5.48E-05 14643 
 
0.501 0.0007 0.0015 6.62E-01 7873 
 
0.507 -0.0027 0.0011 1.41E-02 22516 
rs2187488 8 123,435,673 t c 0.475 -0.0063 0.0014 7.88E-06 16469 
 
0.470 0.0006 0.0011 6.01E-01 11056 
 
0.472 -0.0021 0.0009 1.59E-02 27525 
rs4797232 18 5,822,745 t c 0.649 0.0073 0.0017 2.01E-05 14640 
 
0.648 -0.0001 0.0012 9.07E-01 10894 
 
0.648 0.0023 0.0010 1.78E-02 25534 
rs171500 20 13,018,489 a g 0.312 0.0067 0.0017 9.09E-05 14634 
 
0.263 -0.0002 0.0014 8.69E-01 11060 
 
0.283 0.0025 0.0011 1.92E-02 25694 
rs2822884 21 15,037,883 t c 0.779 -0.0079 0.0019 3.65E-05 14696 
 
0.719 0.0000 0.0013 9.99E-01 11063 
 
0.738 -0.0025 0.0011 2.00E-02 25759 
rs7565375 2 174,405,548 a c 0.570 -0.0063 0.0016 9.23E-05 14639 
 
0.563 0.0000 0.0011 9.93E-01 10994 
 
0.565 -0.0021 0.0009 2.20E-02 25633 
rs1316566 12 93,647,288 a g 0.372 0.0066 0.0016 4.20E-05 14643 
 
0.372 -0.0013 0.0016 3.96E-01 7930 
 
0.372 0.0026 0.0011 2.23E-02 22573 
rs10901371 10 126,933,686 a g 0.628 0.0063 0.0016 9.23E-05 14642 
 
0.627 -0.0001 0.0012 9.23E-01 10811 
 
0.628 0.0022 0.0010 2.28E-02 25453 
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Stage 1 
 
Stage 2 
 
Combined 
SNP CHR position A1 A2 Freq A1 Beta* SE P-value N 
 
Freq A1 Beta* SE P-value N 
 
Freq A1 Beta* StdErr P-value N 
rs17299838 22 24,908,221 c g 0.880 -0.0103 0.0026 8.36E-05 14647 
 
0.920 0.0007 0.0022 7.37E-01 10830 
 
0.904 -0.0038 0.0017 2.29E-02 25477 
rs10187654 2 234,478,798 t c 0.200 0.0079 0.0018 1.31E-05 16526 
 
0.190 -0.0009 0.0014 5.47E-01 11047 
 
0.194 0.0026 0.0011 2.31E-02 27573 
rs2708027 12 86,694,952 a c 0.626 0.0056 0.0014 7.13E-05 16487 
 
0.612 -0.0004 0.0012 7.24E-01 11062 
 
0.618 0.0020 0.0009 2.32E-02 27549 
rs698842 2 50,743,600 a t 0.226 0.0081 0.0019 2.30E-05 14695 
 
0.239 -0.0003 0.0013 8.40E-01 11047 
 
0.235 0.0025 0.0011 2.35E-02 25742 
rs2247050 12 86,694,771 t c 0.626 0.0055 0.0014 9.58E-05 16480 
 
0.612 -0.0004 0.0012 7.32E-01 11062 
 
0.618 0.0020 0.0009 2.56E-02 27542 
rs17045203 2 53,848,324 t c 0.063 0.0135 0.0033 4.86E-05 14697 
 
0.059 -0.0005 0.0024 8.45E-01 11061 
 
0.060 0.0043 0.0019 2.58E-02 25758 
rs12463008 19 49,598,068 a c 0.947 -0.0157 0.0040 9.72E-05 12448 
 
0.953 0.0000 0.0028 1.00E+00 10833 
 
0.951 -0.0051 0.0023 2.59E-02 23281 
rs11710922 3 33,997,987 a t 0.928 0.0126 0.0032 9.23E-05 14680 
 
0.930 -0.0001 0.0022 9.65E-01 11054 
 
0.929 0.0041 0.0018 2.66E-02 25734 
rs9458393 6 162,175,525 t g 0.402 0.0068 0.0017 7.13E-05 14636 
 
0.390 0.0000 0.0011 9.74E-01 11062 
 
0.394 0.0021 0.0009 2.74E-02 25698 
rs1965629 2 234,489,470 a g 0.803 -0.0087 0.0020 1.56E-05 14697 
 
0.809 0.0007 0.0014 6.10E-01 11055 
 
0.807 -0.0025 0.0012 3.32E-02 25752 
rs3843917 6 154,682,502 c g 0.638 0.0070 0.0017 4.34E-05 14684 
 
0.629 -0.0003 0.0012 8.17E-01 11017 
 
0.632 0.0020 0.0010 3.37E-02 25701 
rs831652 5 56,536,183 t c 0.718 0.0078 0.0018 1.69E-05 14678 
 
0.734 -0.0006 0.0013 6.47E-01 11060 
 
0.729 0.0022 0.0010 3.40E-02 25738 
rs9944321 16 64,959,463 a g 0.039 -0.0310 0.0072 1.91E-05 9152 
 
0.018 0.0010 0.0046 8.21E-01 10695 
 
0.024 -0.0082 0.0039 3.42E-02 19847 
rs2287340 2 53,846,363 t g 0.937 -0.0129 0.0032 6.25E-05 14697 
 
0.940 0.0008 0.0024 7.27E-01 11063 
 
0.939 -0.0040 0.0019 3.45E-02 25760 
rs6996401 8 123,417,419 a g 0.526 0.0067 0.0016 3.21E-05 14643 
 
0.530 -0.0005 0.0011 6.77E-01 11062 
 
0.529 0.0019 0.0009 3.89E-02 25705 
rs2822878 21 15,033,311 t c 0.222 0.0079 0.0019 3.65E-05 14697 
 
0.216 -0.0006 0.0014 6.42E-01 11033 
 
0.218 0.0023 0.0011 4.02E-02 25730 
rs187621 5 56,632,446 a g 0.706 0.0074 0.0017 1.54E-05 14681 
 
0.709 -0.0010 0.0012 4.19E-01 10921 
 
0.708 0.0019 0.0010 5.47E-02 25602 
rs1354037 3 195,069,994 t c 0.114 0.0098 0.0025 9.92E-05 14693 
 
0.117 -0.0007 0.0017 6.70E-01 10978 
 
0.116 0.0027 0.0014 5.78E-02 25671 
rs883273 6 154,672,233 a c 0.323 -0.0071 0.0017 3.37E-05 14695 
 
0.328 0.0007 0.0012 5.35E-01 11042 
 
0.326 -0.0018 0.0010 5.91E-02 25737 
rs2975920 9 71,845,911 a g 0.098 -0.0101 0.0025 6.03E-05 16537 
 
0.091 0.0016 0.0020 4.19E-01 10934 
 
0.094 -0.0029 0.0016 6.10E-02 27471 
rs4048532 4 172,809,757 a g 0.170 0.0087 0.0022 8.61E-05 14696 
 
0.158 -0.0009 0.0016 5.60E-01 10564 
 
0.162 0.0024 0.0013 6.17E-02 25260 
rs12685948 9 118,942,952 c g 0.833 -0.0084 0.0021 7.13E-05 14697 
 
0.819 0.0007 0.0015 6.11E-01 11054 
 
0.823 -0.0022 0.0012 6.31E-02 25751 
rs1551900 18 11,597,467 a g 0.612 -0.0070 0.0017 4.34E-05 12980 
 
0.620 0.0007 0.0012 5.54E-01 11058 
 
0.617 -0.0018 0.0010 6.46E-02 24038 
rs6054839 20 7,164,999 c g 0.863 0.0133 0.0033 6.28E-05 10547 
 
0.550 -0.0001 0.0017 9.40E-01 7927 
 
0.615 0.0027 0.0015 7.54E-02 18474 
rs8066615 17 5,760,921 t g 0.067 0.0150 0.0034 1.18E-05 14697 
 
0.067 -0.0020 0.0022 3.83E-01 11039 
 
0.067 0.0032 0.0019 8.80E-02 25736 
rs12602671 17 5,768,371 a g 0.058 0.0142 0.0034 3.37E-05 13292 
 
0.057 -0.0022 0.0024 3.69E-01 11047 
 
0.057 0.0033 0.0020 9.22E-02 24339 
rs243963 4 111,510,330 c g 0.689 -0.0072 0.0017 2.60E-05 14109 
 
0.698 0.0012 0.0012 3.21E-01 11058 
 
0.695 -0.0017 0.0010 9.39E-02 25167 
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Stage 1 
 
Stage 2 
 
Combined 
SNP CHR position A1 A2 Freq A1 Beta* SE P-value N 
 
Freq A1 Beta* SE P-value N 
 
Freq A1 Beta* StdErr P-value N 
rs4833651 4 121,689,810 a c 0.220 -0.0084 0.0020 3.04E-05 12758 
 
0.209 0.0014 0.0014 3.33E-01 10902 
 
0.212 -0.0019 0.0012 1.04E-01 23660 
rs243937 4 111,525,259 a t 0.310 0.0080 0.0018 1.02E-05 12758 
 
0.303 -0.0014 0.0012 2.63E-01 11063 
 
0.305 0.0016 0.0010 1.14E-01 23821 
rs10494937 1 209,711,952 a g 0.943 -0.0224 0.0057 9.53E-05 10547 
 
0.957 0.0011 0.0029 7.17E-01 10880 
 
0.954 -0.0039 0.0026 1.39E-01 21427 
rs604109 11 6,773,971 t c 0.762 -0.0079 0.0020 8.77E-05 12758 
 
0.766 0.0013 0.0013 3.44E-01 11026 
 
0.764 -0.0015 0.0011 1.63E-01 23784 
rs6908357 6 73,176,992 t g 0.909 -0.0119 0.0028 2.44E-05 15335 
 
0.916 0.0030 0.0020 1.38E-01 11059 
 
0.914 -0.0021 0.0016 2.01E-01 26394 
rs10180461 2 143,979,503 t c 0.613 0.0065 0.0016 5.48E-05 14642 
 
0.619 -0.0015 0.0011 1.79E-01 11014 
 
0.617 0.0012 0.0009 2.02E-01 25656 
rs11628114 14 24,577,112 t c 0.121 0.0111 0.0024 4.38E-06 14697 
 
0.119 -0.0032 0.0017 6.88E-02 11041 
 
0.120 0.0017 0.0014 2.19E-01 25738 
rs13409451 2 143,974,109 a g 0.612 0.0066 0.0016 4.20E-05 14642 
 
0.620 -0.0018 0.0012 1.23E-01 10833 
 
0.617 0.0011 0.0009 2.36E-01 25475 
rs17109529 14 24,581,567 t c 0.128 0.0113 0.0025 7.18E-06 14697 
 
0.121 -0.0031 0.0017 7.49E-02 11059 
 
0.123 0.0015 0.0014 2.74E-01 25756 
rs490124 8 23,751,083 a g 0.386 0.0063 0.0016 9.23E-05 14635 
 
0.367 -0.0019 0.0012 1.10E-01 10921 
 
0.374 0.0010 0.0010 2.83E-01 25556 
rs7652290 3 46,274,769 a g 0.686 0.0067 0.0017 9.09E-05 14286 
 
0.705 -0.0020 0.0012 9.99E-02 11060 
 
0.698 0.0010 0.0010 3.26E-01 25346 
rs4609435 1 221,058,314 a g 0.767 0.0180 0.0045 7.13E-05 4144 
 
0.765 -0.0003 0.0013 8.21E-01 11045 
 
0.765 0.0012 0.0013 3.55E-01 15189 
rs4413345 3 46,285,925 t c 0.751 0.0083 0.0019 1.44E-05 14639 
 
0.768 -0.0030 0.0013 2.48E-02 10943 
 
0.763 0.0008 0.0011 4.86E-01 25582 
rs17013203 4 129,521,541 a g 0.176 -0.0084 0.0021 7.13E-05 14697 
 
0.164 0.0031 0.0015 3.94E-02 11011 
 
0.168 -0.0008 0.0012 4.93E-01 25708 
rs463918 4 39,453,011 a g 0.058 -0.0165 0.0042 9.58E-05 10674 
 
0.060 0.0039 0.0024 1.06E-01 11046 
 
0.059 -0.0011 0.0021 5.98E-01 21720 
rs12603905 17 40,560,117 a t 0.789 -0.0079 0.0020 8.77E-05 14568 
 
0.786 0.0035 0.0014 1.10E-02 10912 
 
0.787 -0.0002 0.0011 8.74E-01 25480 
rs2922236 1 11,404,200 c g 0.087 -0.0392 0.0098 7.13E-05 3209 
 
0.492 0.0006 0.0011 6.21E-01 10998 
 
0.487 0.0000 0.0011 9.75E-01 14207 
*Beta for difference between the natural log transformed on- and off-treatment HDL-C levels adjusted for natural log transformed off-treatment HDL-C, 
age, sex, and study specific covariates. The beta reflects the fraction of differential HDL-C lowering in carriers vs. non-carriers of the SNP; a positive beta 
indicates a better statin response (larger HDL-C increase). 
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Supplementary table 6: Summary statistics for all known genome-wide significant genetic variants 
associated with plasma HDL-c levels  
    GLGC  GIST 
# SNP Chr Locus Effect 
allele 
Beta*  Beta† SE P-value 
1 rs3764261 16 CETP a 0.2412  0.0071 0.001 8.82E-13 
2 rs6065906 20 PLTP t 0.0594  0.0061 0.002 0.002391 
3 rs581080 9 TTC39B c 0.0419  0.0058 0.0021 0.00596 
4 rs2652834 15 LACTB a 0.0285  0.006 0.0022 0.006618 
5 rs7241918 18 LIPG t 0.0902  0.0046 0.0019 0.01593 
6 rs16942887 16 LCAT a 0.0831  0.0054 0.0023 0.0194 
7 rs1800961 20 HNF4A t 0.127  0.0093 0.0041 0.02392 
8 rs1883025 9 ABCA1 t 0.0698  0.0041 0.0019 0.03167 
9 rs3136441 11 LRP4 t 0.0545  0.0051 0.0024 0.03436 
10 rs737337 19 ANGPTL8 t 0.0565  0.0063 0.003 0.03654 
11 rs2290547 3 SETD2 a 0.0297  -0.0038 0.0021 0.07159 
12 rs10019888 4 C4orf52 a 0.027  0.0041 0.0023 0.07591 
13 rs838880 12 SCARB1 t 0.0484  0.003 0.0017 0.07891 
14 rs2013208 3 RBM5 t 0.0254  0.0024 0.0014 0.08785 
15 rs702485 7 DAGLB a 0.0243  0.0024 0.0016 0.1353 
16 rs2972146 2 IRS1 t 0.0323  0.002 0.0015 0.1843 
17 rs4983559 14 ZBTB42-AKT1 a 0.0197  0.0021 0.0016 0.1913 
18 rs2923084 11 AMPD3 a 0.0256  0.0027 0.0021 0.2005 
19 rs605066 6 CITED2 t 0.0281  0.002 0.0016 0.2133 
20 rs4142995 7 SNX13 t 0.0263  -0.0017 0.0014 0.2266 
21 rs4759375 12 SBNO1 t 0.056  0.004 0.0033 0.2275 
22 rs13076253 3 ACAD11 a 0.0283  0.0029 0.0024 0.2289 
23 rs9686661 5 MAP3K1 t 0.0283  0.0024 0.002 0.2322 
24 rs2255141 10 GPAM a 0.0337  0.002 0.0017 0.2414 
25 rs4765127 12 ZNF664 t 0.0324  0.002 0.0017 0.2414 
26 rs4846914 1 GALNT2 a 0.0479  0.0018 0.0016 0.2627 
27 rs731839 19 PEPD a 0.022  0.0019 0.0017 0.2658 
28 rs11613352 12 LRP1 t 0.0281  0.0021 0.0019 0.2711 
29 rs17173637 7 TMEM176A t 0.0363  0.0034 0.0032 0.2901 
30 rs3822072 4 FAM13A a 0.0251  0.0017 0.0016 0.2901 
31 rs7134375 12 PDE3A a 0.0207  0.0017 0.0016 0.2901 
32 rs11246602 11 OR4C46 t 0.034  0.0025 0.0024 0.2997 
33 rs12678919 8 LPL a 0.1554  0.0027 0.0027 0.3194 
34 rs12801636 11 KAT5 a 0.0235  -0.0019 0.002 0.3442 
35 rs4148008 17 ABCA8 c 0.028  0.0015 0.0016 0.3506 
36 rs386000 19 LILRA3 c 0.0479  0.0017 0.002 0.3974 
37 rs4129767 17 PGS1 a 0.0237  -0.0013 0.0016 0.4185 
38 rs442177 4 KLHL8 t 0.0215  -0.0012 0.0016 0.4552 
39 rs7134594 12 MVK t 0.0354  -0.0012 0.0016 0.4552 
40 rs970548 10 MARCH8-ALOX5 a 0.0258  0.0013 0.0018 0.4721 
41 rs2925979 16 CMIP t 0.0351  0.0012 0.0017 0.4822 
42 rs17145738 7 MLXIPL t 0.0408  -0.0016 0.0023 0.4885 
43 rs2602836 4 ADH5 a 0.0192  -0.0011 0.0016 0.4936 
44 rs11065987 12 BRAP a 0.0222  -0.001 0.0017 0.5581 
45 rs645040 3 MSL2L1 t 0.0312  0.0011 0.0019 0.5643 
46 rs2814982 6 C6orf106 t 0.0371  0.0013 0.0024 0.5897 
47 rs4731702 7 KLF14 t 0.0294  9.00E-04 0.0017 0.5981 
48 rs6450176 5 ARL15 a 0.0254  9.00E-04 0.0017 0.5981 
49 rs12967135 18 MC4R a 0.0262  0.001 0.0019 0.6003 
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    GLGC  GIST 
# SNP Chr Locus Effect 
allele 
Beta*  Beta† SE P-value 
50 rs1121980 16 FTO a 0.0196  8.00E-04 0.0016 0.6186 
51 rs12328675 2 COBLL1 t 0.0447  -0.0011 0.0022 0.6186 
52 rs1936800 6 RSPO3 t 0.02  -6.00E-04 0.0016 0.7089 
53 rs2293889 8 TRPS1 t 0.0312  6.00E-04 0.0016 0.7089 
54 rs629301 1 SORT1 t 0.0334  -7.00E-04 0.0019 0.7137 
55 rs1689800 1 ZNF648 a 0.0344  6.00E-04 0.0017 0.7253 
56 rs17695224 19 HAS1 a 0.029  -6.00E-04 0.0018 0.74 
57 rs9987289 8 PPP1R3B a 0.0817  9.00E-04 0.0027 0.74 
58 rs12145743 1 HDGF-PMVK t 0.0203  -5.00E-04 0.0017 0.7696 
59 rs4917014 7 IKZF1 t 0.0222  5.00E-04 0.0018 0.7821 
60 rs499974 11 MOGAT2-DGAT2 a 0.0263  5.00E-04 0.0019 0.7933 
61 rs4650994 1 ANGPTL1 a 0.021  4.00E-04 0.0016 0.8034 
62 rs7255436 19 ANGPTL4 a 0.0316  4.00E-04 0.0016 0.8034 
63 rs2606736 3 ATG7 t 0.0246  -4.00E-04 0.0017 0.8148 
64 rs4420638 19 APOE a 0.0669  6.00E-04 0.0028 0.831 
65 rs174546 11 FADS1-2-3 t 0.0391  -3.00E-04 0.0016 0.8519 
66 rs13107325 4 SLC39A8 t 0.0708  4.00E-04 0.0029 0.8908 
67 rs6805251 3 GSK3B t 0.02  -2.00E-04 0.0016 0.901 
68 rs11869286 17 STARD3 c 0.0319  2.00E-04 0.0017 0.9068 
69 rs4660293 1 PABPC4 a 0.0353  2.00E-04 0.0017 0.9068 
70 rs12748152 1 PIGV-NR0B2 t 0.0506  3.00E-04 0.0029 0.918 
71 rs13326165 3 STAB1 a 0.0289  2.00E-04 0.002 0.9207 
72 rs1532085 15 LIPC a 0.1068  1.00E-04 0.0015 0.9471 
73 rs2954029 8 TRIB1 a 0.0401  -1.00E-04 0.0016 0.9504 
74 rs7941030 11 UBASH3B t 0.027  -1.00E-04 0.0016 0.9504 
75 rs1367117 2 APOB a 0.0223  1.00E-04 0.0019 0.9582 
76 rs181362 22 UBE2L3 t 0.038  0 0.002 >0.99 
77 rs964184 11 APOA1 c 0.1065  0 0.0025 >0.99 
78 rs998584 6 VEGFA a 0.026  0 0.0018 >0.99 
GLGC denotes Global Lipids Genetics Consortium; GIST, Genomic Investigation of Statin Therapy. Effect sizes 
are per allele in *s.d. and †staVn-induced fractional HDL-c response. 
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Supplementary figures 
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Supplementary Figure 1: Quantile-quantile plots of the expected versus observed -logP values for all studies participating in the first stage meta-analysis. 
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Supplementary Figure 2: HDL-C change during follow-up for the CETP SNP rs247616 in statin and 
placebo users. 
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Supplementary Note 1. Participating Randomized controlled trials in Phase 1 
Anglo-Scandinavian cardiac Outcomes Trial (ASCOT) 
Of 19,342 hypertensive patients (40–79 years of age with at least three other cardiovascular risk 
factors) who were randomized to one of two antihypertensive regimens in ASCOT, 10,305 with non-
fasting TC concentrations of 6.5 mmol/l or less (measured at the non-fasting screening visit) had been 
randomly assigned additional atorvastatin 10 mg or placebo. These patients formed the lipid-
lowering arm (LLA) of the study. For this genome-wide study only a proportion of United Kingdom, 
Irish, Sweden, Norway, Finland and Denmark consented to participate.  For GWAS data, the available 
samples were genotyped separately, first for the UK and Irish GWAS (ASCOT-UK), and subsequently 
for the Scandinavian GWAS (ASCOT-SC).  Within GIST analyses, ASCOT-UK was used within the 
discovery stage and ASCOT-SC within the replication. In both the GWAS resources there were two 
subpopulations from ASCOT included. The first subpopulation used the RCT data (ASCOT-RCT) and 
included individuals randomized to 10 mg atorvastatin in whom pre-treatment HDL-C was measured 
at the (fasting) randomization visit and on-treatment HDL-C was calculated as the simple average of 
measures at the (fasting) visits 6 months and 12 months post-randomization. Following the end of 
the randomization phase, there was an observational period. The second subpopulation used this 
observational data (ASCOT-OBS) and included all individuals not originally randomized to 10 mg 
atorvastatin (i.e., those randomized to placebo and those not eligible for the LLA) who were 
subsequently prescribed atorvastatin 10 mg during follow-up. For these individuals, pre-treatment 
HDL- C was defined as the measurement on the last visit before or equal to date of starting 
atorvastatin, and on-treatment HDL- C was defined as the measurement taken from the first visit 
after date of starting atorvastatin. 
Collaborative Atorvastatin Diabetes Study (CARDS) 
Methods in CARDS have been described previously 
2, 3
. In brief, 2838 patients with Type 2 diabetes 
and no previous CVD were randomized to receive either placebo or atorvastatin 10mg once daily and 
followed for a median of 3.7 years. Allocation was double blinded. Mean serum LDL- C concentration 
during baseline visits prior to randomization had to be = 4.14mmol/L (160 mg/dl) and serum 
triglycerides = 6.78mmol/L (600mg/dl). After randomization, total cholesterol, HDL-C, and 
triglycerides were measured at one, two, and three months and 6 monthly thereafter. Patients 
attended after an overnight fast. Serum HDL-cholesterol was measured after precipitation of 
apolipoprotein B-containing lipoproteins with heparin manganese with prior removal of very-low-
density lipoproteins (VLDL) by ultracentrifugation in samples from patients whose serum triglycerides 
exceeded 4.00 mmol/ l 
3
.  Once ultracentrifugation was used, it was employed for all subsequent HDL 
measurements in that patient. Serum HDL-cholesterol was calibrated against the Center for Disease 
Control registered laboratory in RIQAS (Pacific Biometrics Ltd, Seattle, WA, USA) using the regression 
equation from 86 comparisons between 1999 and 2003. The genotyping methods in CARDS have 
been described in details elsewhere 
4
. 
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Cholesterol and Atherosclerosis Pharmacogenetics (CAP)
1
  
The trial involved 944 healthy volunteers, 609 of whom were Caucasian 
5
. Participants were aged 30 
and above, who received open label 40 mg simvastatin daily for 6 weeks. They were recruited from 
two clinical sites located in Los Angeles and San Francisco, California, respectively. Screening criteria 
included serum total cholesterol levels of 4.14-10.36 mmol/L (160-400 mg/dL). Lipids, including HDL-
C, were measured twice prior to treatment (at screening and after a two-week run-in period) and 
twice on treatment (4 and 6 weeks), and the averages were used for each time point. Human subject 
approvals were obtained at all participating institutions and all participants signed statements of 
informed consent.  In total, 591 subjects with both lipids and DNA data were available for analysis. 
Discovery genotyping was performed for half of the subjects using beadchip technology 
(HumanHap300 BeadChip , Illumina Inc. San Diego CA) for whole-genome genotyping of 314,621 
tagSNP markers derived from the International HapMap Project. Genome-wide genotyping was 
performed on the remaining half of the samples using the Illumina HumanCNV610-Quad beadchip 
containing 620,901 tagSNPs. SNPs with MAF < 1% and proper information <0.30 (obtained by 
SNPTEST) were excluded from analysis. Imputation was performed using BIMBAM v0.99 with 
reference to HapMap CEU using release 23, build 36. 
PRavastatin INflammation CRP Evaluation study (PRINCE) 
Participants were Caucasians, aged 21 and older, who received 40 mg daily pravastatin for 12 weeks 
6
. They were enrolled from 1143 sites representing 49 states and the District of Columbia, with no 
single site enrolling more than 4 individuals. Recruitment criteria included either an LDL-C 
concentration ≥3.5 mmol/L (>135 mg/dL) or a history of myocardial infarction, stroke, or coronary 
revascularization regardless of baseline LDL-C.  Lipid measurements, including HDL-C, were obtained 
once prior to treatment and once following 12 weeks of treatment. Human subjects approvals were 
obtained at all participating institutions and all participants signed statements of informed consent. 
In total, 1348 participants had DNA available for whole genome-wide association analysis. 
Genotyping and imputation were performed using the same platforms and procedures as for CAP i.e., 
half of the samples with each of the Illumina platforms). 
PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) 
All data come from the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). A detailed 
description of the study has been published elsewhere 
7, 8
. PROSPER was a prospective multicenter 
randomized placebo-controlled trial to assess whether treatment with pravastatin diminishes the risk 
of major vascular events in elderly. Between December 1997 and May 1999, we screened and 
enrolled subjects in Scotland (Glasgow), Ireland (Cork), and the Netherlands (Leiden). Men and 
women aged 70-82 years were recruited if they had pre-existing vascular disease or increased risk of 
such disease because of smoking, hypertension, or diabetes. A total number of 5,804 subjects were 
randomly assigned to pravastatin or placebo. A large number of prospective tests were performed 
including Biobank tests and cognitive function measurements.  
A whole genome wide screening has been performed in the sequential PHASE project with the use of 
                                                          
1
 CAP was designed as a pharmacogenetics study and therefore not a randomized placebo-controlled trial 
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the Illumina 660K beadchip 
9
. Of 5,763 subjects DNA was available for genotyping. Genotyping was 
performed with the Illumina 660K beadchip, after QC (call rate <95%) 5,244 subjects and 557,192 
SNPs were left for analysis. These SNPs were imputed to 2.5 million SNPs based on the HAPMAP built 
36 with MACH imputation software. 
Plasma lipids and lipoproteins were measured twice during the screening phase, i.e. at the beginning 
and end of the single-blind, placebo “run-in” phase according to the standardized Lipid Research 
Clinics protocol. Baseline HDL-C levels were taken as the average of these 2 determinations prior to 
randomization to statin treatment. During follow-up, plasma lipids and lipoproteins were measured 
after 3, 6, 12, 24, and 36 months. Total cholesterol (TC), HDL cholesterol, and triglycerides were 
assessed after an overnight fast, LDL-C was calculated by the Friedewald formula, as previously 
described 
7
.  
Treating to New Targets (TNT) 
The design of the TNT trial has been described in details elsewhere 
10
. In brief, 10 001 patients with 
stable coronary heart disease (CHD) and LDL-C levels <130 mg/dL (3.4 mmol/L) were randomly 
assigned to receive either 10 or 80 mg of atorvastatin per day and were followed up for a median of 
4.9 years. Mean HDL-C levels during treatment were 47 mg/dL (1.22 mmol/L) for the 10- and 80-mg 
groups. At screening, LDL-C, HDL-C, triglycerides (TG), and total cholesterol were measured in all 
subjects in a fasting state. In addition, blood pressure and body mass index as well as other standard 
blood chemistries were measured. All laboratory tests were performed at a central laboratory 
(Medical Research Laboratories, Highland Heights, Ky) certified by the National Heart, Lung, and 
Blood Institute/Centers for Disease Control Part III Program. These were repeated 4 weeks later, at 
randomization, 3 and 6 months post randomization, and annually thereafter. 
After approval by the institutional review committee, informed consent for genetic analysis was 
sought on entry into the trial and 5966 DNA samples were obtained from consenting individuals. A 
subset was chosen for whole-genome analysis based on the cardiovascular events during the course 
of the trial and those individuals were matched 3:1 with controls based on age, gender, treatment 
arm, smoking, diabetes, hypertension, baseline lipid values, baseline glucose levels, and screening 
LDL-C. The Perlegen 322K array genotyping array was used to perform genome-wide genotyping. 
Samples and SNPs will call rate equal or under 98% were removed prior to the analyses. IMPUTE 2 (v. 
2.1.0) and GTOOL (v.0.6.6) were used to impute additional SNPs which were analyzed for their 
association with LDL response with PLINK (v.1.07) 
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Supplementary Note 2. Participating observational studies in phase 1 
Age, Gene/Environment Susceptibility-Reykjavik (AGES)  study 
The Reykjavik Study cohort originally comprised a random sample of 30,795 men and women born in 
1907-1935 and living in Reykjavik in 1967. A total of 19,381 attended, resulting in 71% recruitment 
rate. Between 2002 and 2006, the AGES-Reykjavik study re-examined 5,764 survivors of the original 
cohort who had participated before in the Reykjavik Study 
11
. Serum lipid levels were measured at 
baseline (AGES:2002-2006), and at a follow-up five years later (AGESII:2007-2001). Individuals were 
recruited in the same order. Of the 5,764 participants, 3,664 participants were randomly selected for 
the GWAS. Genotyping was undertaken using the HumanCNV370-Duo (Illumina) at the Laboratory of 
Neurogenetics, Intramural Research Program, at the National Institute of Aging, Bethesda, Maryland. 
Atherosclerosis Risk in Communities (ARIC) study  
The ARIC study is an ongoing population-based cohort of 15,792 predominantly Caucasian and 
African-American males and females aged 45-64 years at baseline and selected using probability 
sampling from four United States communities (Forsyth County NC, Jackson MS, suburban 
Minneapolis MN, and Washington County MD) 
12
. Participants were recruited in 1987-1989 to 
examine cardiovascular and pulmonary disease, patterns of medical care, and disease variation over 
time. Standardized physical examinations and interviewer-administered questionnaires were 
conducted at baseline (1987-1989), three triennial follow-up examinations (1990-1998), and a fifth 
exam (2011-2013). Eligible participants for this effort were from the NC, MN, and MD field centers, as 
only Caucasian participants were examined in this analysis and the MS center only recruited African 
American participants. 
Twelve-hour fasting total cholesterol and HDL were measured as previously described at baseline and 
during the three triennial exams; 
13, 14
 data from the fifth exam did not contribute to this analysis. To 
evaluate the effect of lipid lowering therapy, we selected the first exam at which the participant 
reported using statins. We then used the HDL measure from that examination and the previous 
examination (approximately three years earlier) to calculate the logarithm of HDL before statin 
treatment minus the logarithm of HDL after beginning statin treatment. Participants who reported 
using statins at the baseline visit were excluded, as we did not have a pre-treatment HDL measure to 
evaluate. 
The Affymetrix 6.0 genotype array was used to genotype n=669,450 SNPs that passed quality control 
(sample call rate ≥ 0.95; SNP call rate ≥ 0.90; SNP MAF filter ≥ 0.01, HWE p-value filter ≥ 10
-5
). SNPs 
were imputed based on the HAPMAP build 36 with MACH v1.16 and analyses were performed using 
ProbABEL. 
BioVU 
BioVU is the nation’s largest collection of DNA samples linked to a comprehensive, de-identified 
electronic medical record (EMR) 
15, 16
. BioVU began in 2007 and accrues DNA samples via an opt-out 
model (the design and ethical principles of which have been described previously 
15
 primarily from 
outpatient visits. On September 3, 2013, the biobank contains 151,605 adults linked to de-identified 
mirror images of individual comprehensive EMRs. This database is scrubbed of all Health Insurance 
Portability Accountability Act (HIPAA) identifiers; e.g., if the name “John Smith” appears in the 
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original record, its corresponding record in the synthetic derivative is permanently replaced with a 
tag [NAME AAA, BBB] to maintain the semantic integrity of the text.  
Per BioVU policy, all projects utilizing BioVU samples are required to redeposit their genotyping 
results into the BioVU databases for reuse by other investigators. Of note, 16,701 individuals have 
genome-wide SNP data available on September 3, 2013, and were among the available population 
used for this study. 
Plasma lipid data is extracted from linked de-identified EMRs. Before Treatment HDL-C is defined as 
median HDL-C within an 18 month window before first ever statin mentioned in the EMRs. After 
Treatment HDL-C is defined as median HDL-C within an 18 month window after first ever statin 
mentioned in the EMRs, with right censoring within the 18 month window at the first drug or dose 
changes.  
Statin exposures were derived from electronic prescribing tools and use of the MedEx natural 
language processing tool, which extracts medication references from narrative text 
17
. When using 
MedEx, we apply heuristic rules to identify patients truly receiving medications and filter out adverse 
events, medication discussions, and other non-prescription events. 
Cardiovascular Health Study (CHS) 
The CHS is a population-based cohort study of risk factors for CHD and stroke in adults ≥65 years 
conducted across four field centers 
18
. The original predominantly Caucasian cohort of 5,201 persons 
was recruited in 1989-1990 from random samples of the Medicare eligibility lists; subsequently, in 
1992-1993, an additional predominantly African-American cohort of 687 persons was enrolled for a 
total sample of 5,888. DNA was extracted from blood samples drawn on all participants at their 
baseline examination. In 2007-2008, genotyping was performed at the General Clinical Research 
Center's Phenotyping/Genotyping Laboratory at Cedars-Sinai using the Illumina 370CNV BeadChip 
system on 3980 CHS participants who were free of CVD at baseline, consented to genetic testing, and 
had DNA available for genotyping. Because the other cohorts were predominantly white, the African 
American participants were excluded from this analysis. Thus, for this analysis, the study sample is 
limited to European ancestry participants who used statins during follow up with available genotype 
data as well as on- and off-treatment lipid measures. 
In CHS, the following exclusions were applied to identify a final set of 306,655 autosomal SNPs: call 
rate < 97%, HWE P < 10-5, > 2 duplicate errors or Mendelian inconsistencies (for reference CEPH 
trios), heterozygote frequency = 0, SNP not found in HapMap. Imputation was performed using 
BIMBAM v0.99 with reference to HapMap CEU using release 22, build 36 using one round of 
imputations and the default expectation-maximization warm-ups and runs. 
Plasma lipids and lipoproteins were measured several times during follow-up; HDL-C measurements 
are available from baseline (year 2), year 5, and year 18. Subjects came to the clinic after an 
overnight fast, and blood was obtained on their arrival at the clinic. Samples were shipped weekly, on 
dry ice, to the CHS Central Blood Laboratory at the University of Vermont, where all analyses were 
performed. Plasma total cholesterol and triglyceride (TG) were measured by enzymatic methods on 
an Olympus Demand System (Olympus Corp., Lake Success, N.Y.). HDL-C was measured by an 
enzymatic method after precipitation of apo-lipoprotein B-containing lipoproteins with dextran 
sulfate/magnesium sulfate. LDL-C was calculated according to the Friedewald equation for individuals 
whose serum TG was <4.51mmol/l 
19
.   
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Framingham Heart Study (FHS) 
The methods for recruitment and clinical covariate collection have been described previously for the 
original Framingham Heart Study cohort (5,209 participants ascertained systematically from two-
thirds of the households in the town of Framingham, MA, beginning in 1948)
20
, the Framingham 
Heart Study Offspring cohort (5,124 children of the original cohort, and spouses of those children, 
beginning in 1972)
21
, and the Third Generation cohort (4,095 children of the Offspring cohort, 
beginning in 2002)
22
. The current study was conducted in 1266 participants recruited in the Offspring 
Cohort from Exam 4 (1987-1991) through Exam 8 (2005-2008) and 266 participants in the Third 
Generation from Exam 1 (2002-2005) and Exam 2 (2008-2011). HDL-C was collected at each exam 
using standard protocols. To evaluate the effect of lipid lowering therapy, we selected the first exam 
at which a person reported using lipid lowering medication. It is assumed that most of the therapy 
during this time was statin, but we did not have specific data on which medications were used except 
for Exams 8 in the Offspring and 1 and 2 for the Third Generation. Then we used the HDL-C measure 
from that examination and the previous exam (approximately 3-4 years before) to calculate the 
logarithm of HDL-C before lipid lowering treatment minus the logarithm of HDL-C after the beginning 
use of lipid lowering treatment. This trait was analysed in mixed effects linear regression models 
(accounting for familial relationships) for all genetic variants in the CEU sample of the Phase 2 
HapMap Release 22. We adjusted for sex, age, time between the HDL-C measurements and Principal 
Component 7 to control for population substructure. 
Genotyping was conducted for the SNP Health Association Resource (SHARe) project 
(http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000007.v20.p8) using the 
Affymetrix 500K mapping array (250K Nsp and 250K Sty arrays) and the Affymetrix 50K supplemental 
gene focused array on a total of 9,274 individuals from all three cohorts. BRLMM was used to call 
these data. To evaluate population substratification, we conducted principal component analyses 
using EIGENSTRAT 
23
 on the genotypes from 882 unrelated participants. We estimated the first 10 
principal components and applied the loadings of these components to all genotyped participants.  
Finally, we evaluated whether any of these principal components were associated with the difference 
in the logarithms of HDL before and after lipid lowering initiation. Only Principle Component 7 was 
associated with HDL-C and was thus included in the regression model. Genotyping resulted in 
503,551 SNPs with successful call rate >95% and HWE P>1.0x10-6 in 8,481 individuals with call rate 
>97%. Imputation of 2,543,887 autosomal SNPs in HapMap release 22, CEU sample was conducted 
using the algorithm implemented in MACH (version 1.0.15). From a total of 534,982 genotyped 
autosomal SNPs in Framingham, 378,163 SNPs were used in imputation after filtering out 15,586 
SNPs (HWE P<1.0x10
-6
), 64,511 SNPs (missingness >0.03), 45,361 SNPs (mishap P<1.0x10
-9
), 4,857 
SNPs (>100 Mendel errors), 67,269 SNPs (frequency <0.01), 2 SNPs (due to strand issues upon 
merging data with HapMap), and a further 13,394 SNPs that were not present on HapMap. We used 
200 biologically unrelated participants to estimate the parameters of the imputation model and 
subsequently applied the estimated parameters to obtain imputed SNPs for all 8,481 participants. 
The Framingham Heart Study, including genetic association studies of Framingham phenotypes, was 
approved by the institutional review boards of Boston University and the National Institutes of 
Health. All participants provided written informed consent. 
Health Aging and Body Composition (Health ABC) Study 
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Health ABC is a NIA-sponsored ongoing cohort study of  the factors that contribute to incident 
disability and the decline in function of healthier older persons, with a particular emphasis on 
changes in body composition in old age. Health ABC enrolled well-functioning, community-dwelling 
black (n=1281) and white (n=1794) men and women aged 70-79 years between April 1997 and June 
1998. Participants were recruited from a random sample of white and all black Medicare eligible 
residents in the Pittsburgh, PA, and Memphis, TN, metropolitan areas. The key components of Health 
ABC include a baseline exam, annual follow-up clinical exams, and phone contacts every 6 months to 
identify major health events and document functional status between clinic visits. HDL cholesterol 
was measured from plasma stabilized with EDTA in the entire cohort using the VITROS CHOL slide 
(Ortho-Clinical Diagnostics, Inc.). GWAS data are available from 1663 white participants. Genomic 
DNA was extracted from buffy coat collected using PUREGENE® DNA Purification Kit during the 
baseline exam. Genotyping was performed by the Center for Inherited Disease Research (CIDR) using 
the Illumina Human1M-Duo BeadChip system. Samples were excluded from the dataset for the 
reasons of sample failure, genotypic sex mismatch, and first-degree relative of an included individual 
based on genotype data. Genotyping was successful for 1,151,215 SNPs in 1663 unrelated. 
Imputation was done for the autosomes using the MACH software version 1.0.16. SNPs with minor 
allele frequency ≥ 1%, call rate ≥97% and HWE p≥10-6 were used for imputation. HapMap II phased 
haplotypes were used as reference panels. For EAs, genotypes were available on 914,263 high quality 
SNPs for imputation based on the HapMap CEPH reference panel (release 22, build 36). A total of 
2,543,887 SNPs in EAs are available for analysis. 
Heart and Vascular Health (HVH) Study 
HVH is a case-control study set in Group Health (GH), a large integrated health care system in 
Washington State, and is comprised of incident myocardial infarction (MI) and stroke cases with a 
shared common control group. All participants were GH members and aged 30-79 years. MI and 
stroke cases were identified from hospital discharge diagnosis codes and were validated by medical 
record review. Controls were a random sample of GH members frequency matched to MI cases on 
age (within decade), sex, treated hypertension, and calendar year of identification. The index date for 
controls was a computer-generated random date within the calendar year for which they had been 
selected. For MI cases, the index date was the date of admission for the first acute MI. Participants 
were excluded if they were recent enrollees at GHC, had a history of prior MI or stroke, or if the 
incident event was a complication of a procedure or surgery. Methods for the study have been 
described previously. 
24-26
 
Eligibility and risk factor information were collected by trained medical record abstractors from a 
review of the GH medical record using only data available prior to the index date and through a 
telephone interview.  Medication use was ascertained using computerized GH pharmacy records.  A 
venous blood sample was collected from all consenting subjects, and DNA was extracted from white 
blood cells using standard procedures. 
Genotyping was performed at the General Clinical Research Center's Phenotyping/Genotyping 
Laboratory at Cedars-Sinai using the Illumina 370CNV BeadChip system. Genotypes were called using 
the Illumina BeadStudio software. Samples were excluded from analysis for sex mismatch or call rate 
< 95%. The following exclusions were applied to identify a final set of 301,321 autosomal SNPs: call 
rate < 97%, HWE P < 10-5, > 2 duplicate errors or Mendelian inconsistencies (for reference CEPH 
trios), heterozygote frequency = 0, SNP not found in HapMap, inconsistencies across genotyping 
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batches.  Imputation was performed using BIMBAM with reference to HapMap CEU using release 22, 
build 36 using one round of imputations and the default expectation-maximization warm-ups and 
runs.    
Plasma lipids and lipoproteins were measured over the course of general care at Group Health and 
were obtained from the outpatient medical record and/or Group Health laboratory database.  
Multi-Ethnic Study of Atherosclerosis (MESA) 
The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical 
cardiovascular disease (disease detected non-invasively before it has produced clinical signs and 
symptoms) and the risk factors that predict progression to clinically overt cardiovascular disease or 
progression of the subclinical disease. MESA researchers study a diverse, population-based sample of 
6,814 asymptomatic men and women aged 45-84. Thirty-eight percent of the recruited participants 
were white, 28 percent African-American, 22 percent Hispanic, and 12 percent Asian, predominantly 
of Chinese descent 
27
. Participants were recruited from six field centers across the United States and 
followed-up three times with an average time period of follow-up of 2 years between each visit. Data 
from four visits (exam1 to exam4) was used for the analysis. Subjects on statin treatment at the time 
point of follow-up visit and off treatment at the previous visit were qualified for inclusion. Phenotype 
(lipids measures before and after statin treatment) and genotype data were available for 360 
Caucasian subjects. The tenets of the Declaration of Helsinki were followed and institutional review 
board approval was granted at all MESA sites. Written informed consent was obtained from each 
participant. 
Genotyping was performed using the Affymetrix Genome-Wide Human SNP Array 6.0. IMPUTE 
version 2.1.0 was used to perform imputation for the MESA Caucasian participants (chromosomes 1-
22) using HapMap Phase I and II - CEU as the reference panel (release #24 - NCBI Build 36 (dbSNP 
b126)). SNPs with MAF less than 0.02 or HWE p value less than 0.001 were removed from the 
analysis.  
Rotterdam study 
The Rotterdam Study is a prospective population-based cohort study of chronic diseases in the 
elderly population. From 1990 to 1993, 7983 inhabitants of the suburb Ommoord in Rotterdam, the 
Netherlands, aged 55 years or older, entered the Rotterdam Study (RS-I), and have been continuously 
followed since then. Medication prescription data were obtained from all seven fully computerized 
pharmacies in the Ommoord suburb. These pharmacies dispense the prescriptions of more than 99% 
of all participants. Information on all filled prescriptions from January 1st 1991 until June 1st 2008 
was available and included information on the product name of the drug, the Anatomical 
Therapeutical Chemical code, the amount dispensed, the prescribed dosage regimen and the date of 
dispensing. Furthermore, in 2000, an extended cohort was enrolled, the Rotterdam Study II (RS-II). 
3011 inhabitants entered the study and have been continuously followed since then. Detailed 
information on design, objectives and methods of this study have been described before 
28, 29
. The 
Rotterdam Study has been approved by the medical ethics committee according to the Wet 
Bevolkingsonderzoek: ERGO (Population Screening Act: Rotterdam Study), executed by the Ministry 
of Health, Welfare and Sports of the Netherlands. All participants gave informed consent to 
participate in the study and to obtain information from treating physicians and pharmacy records, 
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separately. 
Lipid measurements were obtained from all participants at each visit. Fasting total cholesterol, HDL-
cholesterol and triglyceride levels were determined using enzymatic procedures (Hitachi Analyzer, 
Roche Diagnostics).  
At baseline examination of the Rotterdam Study, blood was taken from which genomic DNA was 
extracted, using the salting-out method 
30
. Microarray genotyping was performed in both Rotterdam 
Study cohorts, using the Infinium II HumanHap550K Genotyping BeadChip version 3 (Illumina Inc., 
San Diego, CA, USA). Genotyping procedures were followed according to the manufacturer’s 
protocols. Microarray genotyping procedures in the Rotterdam Study have been previously described 
31
. 
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Supplementary Note 3. Participating studies in Phase II 
Genetics of Diabetes Autdit and Research Tayside Study (GoDARTS)  
The GODARTS cohort was ascertained from the Diabetes Audit and Research Tayside Study (DARTS) 
and has been described before 
32
. Each individual in Go-DARTS has multiple measures of clinical 
parameters recorded over a period of time during the course of their clinical management. These 
clinical parameters were BMI, total cholesterol, high-density lipoprotein cholesterol (HDL-C).  For the 
purpose of this study we included the baseline HDL-C as the HDL-c at first study visit and follow-up 
HDL as HDL the highest HDL-c attained during the follow-up period. The Go-Darts data were 
genotyped on affymetrix (N=3094) and illumina platform (n=3039). 
 
Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin 
(JUPITER) population 
The study population was derived from JUPITER, an international, randomized, placebo-controlled 
trial of rosuvastatin (20mg/day) in the primary prevention of cardiovascular disease conducted 
among apparently healthy men and women with LDL-C < 130 mg/dL and hsCRP ≥ 2 mg/L 
33
. 
Individuals with diabetes or triglyceride concentration >500mg/dL were also excluded. Approximately 
71.2% of JUPITER participants had European ancestry among whom 71.4% provided DNA and 
consent for genetic analysis. The present analysis includes only individuals with genotype information 
who had verified European ancestry (see below) and who were deemed compliant with the study 
protocol as judged by on the basis of pill counts and reported absence of non-trial statin use, i.e. 
information that was independent of LDL-C reduction.  After applying these restrictions, 3417 statin- 
and 3388 placebo-allocated participants remained for analysis with HDL-C measures at baseline and 
follow-up. 
Per study protocol, all JUPITER participants had standard lipid measurements made in a core 
laboratory facility prior to randomization and again after one year of placebo or rosuvastatin 
treatment. HDL-C was after heparin-manganese precipitation of apolipoprotein B-containing 
particles.  
Genotyping in the JUPITER population was performed using the Omni 1M Quad platform (Illumina, 
San Diego) as described previously 
34
. In the final data used for analysis, samples were retained if 
>98% of the SNPs had successfully genotype, while SNPs were retained if genotyping was successful 
in >90% of the samples.  Of JUPITER participants with self-reported European ancestry over 99% had 
successful genotyping and verification of their ancestry using multi-dimensional scaling procedures in 
PLINK 
35
 applied to 1,067 ancestry informative SNPs from HapMap3. Among JUPITER participants with 
verified European ancestry, rs7412, which distinguishes the APOE E2 from E3/E4 genotypes deviated 
from Hardy-Weinberg equilibrium, likely due to the ascertainment criteria related to LDL-C levels in 
JUPITER. This SNP was included in the final data only after manual inspection of genotyping clusters. 
Sub-European ancestral stratification was estimated using the principal component approach in 
EIGENSTRAT 
23
. Genotypes for SNPs in the 1000 genomes pilot data (release 2010-03) were imputed 
with MaCH v. 1.0.16 
36
. 
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